

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
1	ANESTHESIOLOGY	GUCEV, GLIGOR MD	401760	01/23/06	GLAXOSMITHKLINE	PHASE III STUDY TO EVALUATE SAFETY AND EFFICACY OF GW627368
2	ANESTHESIOLOGY	LUMB, PHILIP MB	400600	12/03/04	PROCTOR & GAMBLE	STUDY OF 2MG/KG BOLUS PLUS 24-HOUR 0.05MG/KG/HR INFUSION OF PEXELIZUMAB
3	ANESTHESIOLOGY	LUMB, PHILIP MB	495000	11/19/04	THE MEDICINES COMPANY	EVALUATION OF CLEVELOX IN PERIOPERATIVE TREATMENT OF HYPERTENSION ASSESSING SAFETY
4	ANESTHESIOLOGY	LUMB, PHILIP MB	400220		ANESTHESIOLOGY TITHING ACCOUNT	DEPARTMENT OF ANESTHESIOLOGY TITHING ACCOUNT
5	ANESTHESIOLOGY	LUMB, PHILIP MB	405800	12/29/04	GLAXOSMITHKLINE	PHASE II STUDY OF OF ORAL (25& INTRAVENOUS (3MG AND 18MG) FORMULATIONS OF THE NEUROKININ
6	ANESTHESIOLOGY	LUMB, PHILIP MB	401790	01/31/06	ORGANON	COMPARING RECOVERY FROM 1.2 MG.KG-1 ROCURONIUM FOLLOWED BY 16MG.KG-1
7	ANESTHESIOLOGY	LUMB, PHILIP MB	401685	01/05/06	THE MEDICINES COMPANY	EVALUATION OF CLEVELOX IN HYPERTENSION ASSESSING ECLIPSE - NIC
8	ANESTHESIOLOGY	LUMB, PHILIP MB	401285	09/07/05	ORGANON	PHASE III TRIAL EVALUATE THE EFFICACY & SAFETY OF ORG25969 AT THE END OF SURGICAL PROCEDURE
9	ANESTHESIOLOGY	LUMB, PHILIP MB	407100	06/15/05	CRITICAL THERAPEUTICS	STUDY OF CTI-01 IN PATIENTS UNDERGOING MAJOR CARDIAC SURGERY ON CARDIOPULMONARY BYPASS
10	ANESTHESIOLOGY	RAPHAEL, DAVID MD	745800	07/01/02	FOUNDATION FOR ANESTHESIA	A 3-D TEACHING ATLAS OF THE BRACHIAL PLEXUS USING MR NEUROGRAPHY
11	ANESTHESIOLOGY	RICHEIMER, STEVEN H MD	401690	01/06/06	ADVANCED BIONICS	SUBCUTANEOUS STIMULATION FOR MYOFASCIAL BACK PAIN: A PILOT FEASIBILITY STUDY
	<b>ANESTHESIOLOGY Count</b>	11				
12	BIOKINESIOLOGY & PHYS	KULIG, KORNELIA J PH.D	227500	10/26/05	HRA SEED GRANTS	LUMBAR MULTIFIDUS ATROPHY AND FATIGABILITY IN PERSONS WITH LOWER BACK PAIN
	<b>BIOKINESIOLOGY &amp; PHYS</b>	1				
13	CARDIO THORACIC SURG	COHEN, ROBBIN G MD	496500	08/27/04	MEDTRONIC	EXERCISE HEMODYNAMICS IN PATIENTS UNDERGOING AORTIC VALVE REPLACEMENT
14	CARDIO THORACIC SURG	SMITH, MICHAEL J	400960	10/17/05	DOMPE	PHASE 2 STUDY OF REPERTAXIN IN THE PREVENTION OF PRIMARY GRAFT DYSFUNCTION
15	CARDIO THORACIC SURG	STARNES, VAUGHN A MD	401600	12/03/04	PROCTOR & GAMBLE	STUDY OF 2 MG/KG BOLUS PLUS 24-HOUR 0.05 MG/KG/HR INFUSION OF PEXELIZUMAB IN PATIENTS
16	CARDIO THORACIC SURG	STARNES, VAUGHN A MD	498400	11/04/04	AVANT IMMUNOTHERAPEUTICS	PHASE II OF HUMAN RECOMBINANT SOLUBLE COMPLEMENT RECEPTOR TYPE 1 (TP10)
	<b>CARDIO THORACIC SURG</b>	4				
17	COLORECTAL SURGERY	KAISER, ANDREAS MD	400690	11/07/05	WYETH - AYERST RESEARCH	STUDY OF TIGECYCLINE VS. CEFTRIAXONE SODIUM PLUS METRONIDAZOLE
	<b>COLORECTAL SURGERY</b>	1				
18	EMERGENCY MEDICINE	HENDERSON, SEAN O	227400	07/17/04	HRA SEED GRANTS	ASTHMA: EFFECT OF GENOTYPE ON RESPONSE TO THERAPY
19	EMERGENCY MEDICINE	HENDERSON, SEAN O	400770		MILLENNIUM PHARMACEUTICALS	EARLY GLYCOPROTEIN IIB/III INHIBITION IN NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME
20	EMERGENCY MEDICINE	NEWTON, EDWARD J MD	401460	10/20/05	BIOSITE INCORPORATED	SAMPLE COLLECTION FOR STUDY ON ACUTE PANCREATITIS, ACUTE CHOLECYSTITIS AND ISCHEMIC
21	EMERGENCY MEDICINE	SHIH, KAREN MD	401415	10/13/05	BERKELEY RESEARCH CONSORTIUM	
22	EMERGENCY MEDICINE	STONE, SUSAN C	228000	08/01/05	HRA SEED GRANTS	ASSESSMENT OF PRE-HOSPITAL WORKERS TRAINING SKILLS IN HONORING ADVANCE DIRECTIVES
	<b>EMERGENCY MEDICINE C</b>	5				
23	MEDICAL ADMINISTRATIO	BERNSTEIN, SOL MD	646000	06/23/94	ARTS & HUMANITIES FUNDS	ENDOWMENT FUND FOR ARTS AND HUMANITIES
24	MEDICAL ADMINISTRATIO	RAMER, LOIS RN	838600	03/23/01	UNIVERSITY OF ARKANSAS	MI SYMPTOMS IN WOMEN: DISPARITIES IN WOMEN OF COLOR
	<b>MEDICAL ADMINISTRATIO</b>	2				

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
25	MEDICINE	AKMAL, MOHAMMAD MD	465900	11/08/02	ORTHO BIOTECH PRODUCTS, L.P	CORRECTION OF HEMOGLOBINAND OUTCOMES IN RENALINSUFFICIENCY (CHOIR)
26	MEDICINE	AKMAL, MOHAMMAD MD	499300	10/18/04	SHIRE US	PHASE IIIB STUDY W/T OPEN-LABERUN-IN & LONG TERM EXTENSIONPHASE OF LANTHANUM CARBONATE
27	MEDICINE	AKMAL, MOHAMMAD MD	401185	11/03/05	AMGEN INC.	TRIAL TO REDUCECARDIOVASCULAR EVENTS WITHARANESP THERAPY
28	MEDICINE	APARICIO, ANA MD	227800	11/17/04	HRA SEED GRANTS	PILOT STUDY OF BIOMARKERS OFEPIGENETIC THERAPY INPERIPHERAL BLOOD & ORAL MUCOSA
29	MEDICINE	APARICIO, ANA MD	401145		SANOFI-AVENTIS	
30	MEDICINE	APARICIO, ANA MD	401850	02/08/06	US ONCOLOGY	VIDAZA TO RESTORE RESPONSETO HORMONAL THERAPY
31	MEDICINE	APARICIO, ANA MD	401225	11/14/05	PHARMION CORPORATION	RANDOMIZED OPEN LABEL TO ASSESPHARMACOKINETICS AND DOSE-PROPORTIONALITYOF AZACITIDINE
32	MEDICINE	ARKFELD, DANIEL MD	683600	10/28/97	IMMUNEX RESEARCH AND	OPEN LABEL EXTENSION TREATMENTWITH TN FR: FC FOR ....
33	MEDICINE	BARBERS, RICK MD	470500	05/13/03	LOS ANGELES SOCIETY OF ALLE	EDUCATIONAL ACCOUNT
34	MEDICINE	BARBERS, RICK MD	401140	12/05/05	ASTHMATIX	SAFETY & EFFECTIVENESS THE ALAIR SYSTEM FOR THE TREATMENTOF ASTHMA
35	MEDICINE	BUCHANAN, THOMAS A MD	598700	12/01/88	GCRC ACCOUNT	GENERAL CLINICAL RESEARCHCENTER (GCRC) ACCOUNT
36	MEDICINE	BUCHANAN, THOMAS A MD	519010	11/01/96	GCRC ACCOUNT	GCRC ACCOUNT- CORE LAB SUBACCOUNT MOLECULAR MEDICINE
37	MEDICINE	BUCHANAN, THOMAS A MD	669700	11/18/96	PARKE-DAVIS	TROGLITAZONE & ATHEROSCLEROSISSTUDY
38	MEDICINE	BUCHANAN, THOMAS A MD	655000	06/01/95	ENDOCRINOLOGY TITHING ACCO	DIVISION OF ENDOCRINOLOGYTITHING ACCOUNT
39	MEDICINE	BUCHANAN, THOMAS A MD	437700	12/20/00	TAKEDA	PROGLITAZONE IN WOMEN WITHPRIOR GESTATIONAL DIABETES
40	MEDICINE	BUCHANAN, THOMAS A MD	485700	02/04/04	TAKEDA	THE ACT NOW STUDY: ACTOSNOW FOR PREVENTION OF DIABETES
41	MEDICINE	BUCHANAN, THOMAS A MD	519000	07/01/91	GCRC ACCOUNT	GENERAL CLINICAL RESEARCHCENTER (GCRC) CORE LAB ACCOUNT
42	MEDICINE	CADDEN, JOSEPH J MD	401375	10/14/05	TIBOTEC PHARMACEUTICALS	EARLY ACCESS OF TMC114 WITHRITONAVIR AND ANTIRETROVIRALSIN HIV-1 SUBJECTS
43	MEDICINE	CAMPESE, VITO M MD	477300	10/06/03	OTSUKA AMERICA	EFFICACY & SAFETY STUDY OF THEEFFECTS OF ORAL TOLVAPTAN INPATIENTS WITH HYPONATREMIA
44	MEDICINE	CAMPESE, VITO M MD	456400	02/25/02	PHARMACIA & UPJOHN	CELECOXIB VS ROFECOXIB ANDDIETARY SODIUM ON BLOODPRESSURE IN ELDERLY
45	MEDICINE	CAMPESE, VITO M MD	488600	05/09/05	BOEHRINGER INGELHEIM	ONE YEAR TREATMENT TRIAL TOCOMPARE MICARDIS (TELMISARTAN)80 MG VERSUS COZAAR (LOSARTAN)
46	MEDICINE	CAMPESE, VITO M MD	400890		KERYX BIOPHARMACEUTICALS	THE COLLABORATIVE STUDY GROUPTRIAL: THE EFFECT OF SULODEXID IN PATIENTS WITH TYPE 2 DIA
47	MEDICINE	CAMPESE, VITO M MD	409800	06/22/05	UNIVERSITY OF OXFORD	STUDY OF HEART AND RENALPROTECTION (SHARP)
48	MEDICINE	CAMPESE, VITO M MD	401765	01/24/06	KERYX BIOPHARMACEUTICALS	THE EFFECT OF SULODEXIDE INOVERT TYPE 2 DIABETICNEPHROPATHY
49	MEDICINE	CAMPESE, VITO M MD	480500	11/04/03	BOEHRINGER INGELHEIM	FORCED-TITRATION TRIAL TOCOMPARE MICARDIS PLUS /MICARDIS HCT TO DIOVAN HCT
50	MEDICINE	CAMPESE, VITO M MD	401830	02/07/06	ABBOTT LABORATORIES	FENOFIBRIC ACID AND SIMVASTATICOMBINATION THERAPY IN SUBJECTWITH MIXED DYSLIPIDEMIA
51	MEDICINE	CAMPESE, VITO M MD	401345		NABI BIOPHARMACEUTICALS	STUDY OF CALCIUM ACETATE(PHOSLO) ON PHOSPHORUS LEVELS IN SUBJECTS WITH KIDNEY DISEA
52	MEDICINE	CAMPESE, VITO M MD	401095		ASTRA ZENECA PHARMACEUTICA	PHASE III STUDY OF ROSUVASTA-TIN (CRESTOR®) 20 MG
53	MEDICINE	CHUNG, CATHIE T MD	401030		GLAXOSMITHKLINE	PHASE III STUDY COMPARING GW572016 AND CAPECITABINE (XELODA)VERSUS CAPECITABINE IN WOMEN
54	MEDICINE	CHUNG, CATHIE T MD	401005		NOVARTIS PHARMACEUTICALS C	PHASE 3 STUDY OF RAD001 IN COMBINATION WITH LETROZOLE TO IN-VESTIGATE THE VALUE OF RAD001
55	MEDICINE	CHUNG, CATHIE T MD	401755	01/23/06	AMERICAN BIOSCIENCES, INC	PHASE II TRIAL ADMINISTRATIONOF ABI-007 IN COMBINATION WITHBEVACIZUMAB IN WOMEN W/ CANCER

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
56	MEDICINE	CHUNG, CATHIE T MD	400595	09/20/05	PFIZER INC	PHASE 2 STUDY OF AG-013736IN COMBINATION W/T DOCETAXELALONE IN PATIENTS
57	MEDICINE	DOUER, DAN MD	452700	12/03/01	CELL THERAPEUTICS, INC	ARSENIC TRIOXIDE IN PATIENTSWITH APL IN MOLECULARRELAPSE.....
58	MEDICINE	DOUER, DAN MD	496600	11/15/04	ENZON, INC.	TREATMENT OF NEWLY DIAGNOSEDADULT ACUTE LYMPHOBLASTICLEUKEMIA
59	MEDICINE	DOUER, DAN MD	400880	11/11/05	SCHERING PLOUGH RESEARCH	A PIVOTAL RANDOMIZED STUDY OF LONAFARNIB (SCH 66336) VS.PLACEBO TREATMENT OF MDS
60	MEDICINE	DOUER, DAN MD	400715	07/01/05	STRUCTURAL GENOMIX, INC	PHASE 2 STUDY OF TROXATYLTROXACITABINE) ADMINISTERED BYCONTINUOUS INFUSION IN PATIENT
61	MEDICINE	DOUER, DAN MD	401475	10/21/05	XANTHUS LIFE SCIENCES	STUDY OF AMONAFIDE L-MALATEWITH CYTARABINE IN SUBJECTSWITH SECONDARY (AML)
62	MEDICINE	DOUER, DAN MD	401390		TIBOTEC PHARMACEUTICALS	
63	MEDICINE	DOUER, DAN MD	401680	01/04/06	HANA BIOSCIENCES, INC.	PHASE I/II STUDY OF PT-523(TALOTREXIN) IN PATIENTS WITHREFRACTORY LEUKEMIA
64	MEDICINE	DOUER, DAN MD	401575	11/18/05	CEPHALON, INC.	STUDY OF ORAL CEP-701ADMINISTERED WITH STANDARDCHEMOTHERAPY TO PATIENTS
65	MEDICINE	DOUER, DAN MD	401480	10/21/05	MGI PHARMA BILOGICS, INC.	PHASE 3 TRIAL OF DECITABINEFOR THE TREATMENT OF OLDERPATIENTS WITH (AML)
66	MEDICINE	DOUER, DAN MD	401450	10/18/05	ORTHO BIOTECH PRODUCTS, L.P	PHASE I STUDY OF ZARNESTRA INCOMBINATION WITH LDACPATIENTS WITH MDS AND AML
67	MEDICINE	DOUER, DAN MD	400180	03/31/05	VION PHARMACEUTICALS	RANDOMIZED STUDY OF CLORETAZIN& CYTOSINE ARABINOSIDE (ARAC)PATIENTS ACUTE MYELOID LEUKEMI
68	MEDICINE	DOUER, DAN MD	495100	09/02/04	ORTHO BIOTECH PRODUCTS, L.P	PILOT STUDY EVALUATION OFLATE PROCREDIT INJECTION INANEMIC PATIENTS
69	MEDICINE	DOUER, DAN MD	460600	06/07/02	CELL THERAPEUTICS, INC	ARSENIC TRIOXIDE W/ASCORBICACID IN THE TRTMENT OF ADULTSNON-APL ACUTE MYELOGENOUS
70	MEDICINE	DOUER, DAN MD	477400	08/18/03	CELL THERAPEUTICS, INC	PHASE I STUDY OF TRISENOXINJECTION IN ADULT CANCERPATIENTS W/T RENAL DYSFUNCTION
71	MEDICINE	DOUER, DAN MD	481500	11/18/03	JOHNSON & JOHNSON CONSUME	PHASE II STUDY OF FARNESYLTRANSFERASE INHIBITOR ZARN-ESTRA (R115777)
72	MEDICINE	DURAIRAJ, ALEX MD	400940	10/14/05	CARDIOVASCULAR RESEARCH	HARMONIZING OUTCOMES WITHREVASCLARIZATION AND STENTS
73	MEDICINE	DURAIRAJ, ALEX MD	400942		CARDIOVASCULAR RESEARCH	INFLAMMATORY AND HEMOSTATICBIOMARKER SUB-STUDY
74	MEDICINE	DURAIRAJ, ALEX MD	400941		CARDIOVASCULAR RESEARCH	THE INTRAVASCULAR ULTRASOUNDSUB-STUDY : HEALTH ECONOMICSSUB-STUDY
75	MEDICINE	EHRESMANN, GLENN	400130	04/08/05	IMMUNEX CORPORATION	PHASE 4 STUDY EVALUATING THEEFFECTIVENESS & SAFETY OF EN-BREL (ETANERCEPT) 50 MG
76	MEDICINE	EL-KHOUEIRY, ANTHONY	401745	01/18/06	BRISTOL-MYERS SQUIBB	PHARMACOKINETICS ANDPHARMACODYNAMIS OF BMS-582664IN PATIENTS WITH CANCER
77	MEDICINE	EL-KHOUEIRY, ANTHONY	401665	01/03/06	BRISTOL-MYERS SQUIBB	PHASE 1B COMBINATION STUDYWITH OUR VEGF INHIBITOR ANDCHEMOTHERAPY IN PATIENTS W/ GI
78	MEDICINE	EL-SHAHAWY, MOHAMED	459000	04/15/02	NOVARTIS PHARMACEUTICALS C	REGISTRYOF SIMULECT USE INLIVING DONOR RENAL TRANSPLANTS
79	MEDICINE	EL-SHAHAWY, MOHAMED	402600	03/02/05	LA JOLLA PHARMACEUTICAL CO	TRIAL OF 100MG AND 300MG OFLJP 394 IN SYSTEMIC LUPUSERYTHEMATOSUS (SLE) PATIENTS
80	MEDICINE	EL-SHAHAWY, MOHAMED	400080		NOVARTIS PHARMACEUTICALS C	TWENTY-SIX WEEK STUDY OFCONVERTING POST-KIDNEY & LIVERTRANSPLANT PATIENTS
81	MEDICINE	EL-SHAHAWY, MOHAMED	496300	10/15/04	NOVARTIS PHARMACEUTICALS C	SIX MONTH STUDY TO COMPAREINCIDENCE NEW ONSET DIABETESMELLITUS & GLUCOSE METABOLISM
82	MEDICINE	EL-SHAHAWY, MOHAMED	466000	11/08/02	ORTHO BIOTECH PRODUCTS, L.P	CORRECTION OF HEMOGLOBINAND OUTCOMES IN RENALINSUFFICIENCY (CHOIR)

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
83	MEDICINE	EL-SHAHAWY, MOHAMED	400955		NUVELO	PHASE 3 OF THE STUDY DRUG IN SUBJECTS WITH OCCLUDED CENTRAL VENOUS ACCESS DEVICES
84	MEDICINE	EL-SHAHAWY, MOHAMED	400895		NOVARTIS PHARMACEUTICALS	STUDY OF THE SAFETY, TOLERABILITY & EFFICACY OF MYFORTIC®(ERL080) WITH SIMULECT®
85	MEDICINE	ELKAYAM, URI MD	493200	06/18/04	MEDTRONIC	CHRONICLE OFFERS MANAGEMENT TO PATIENTS W/T ADVANCED SIGNS & SYMPTOMS OF HEART FAILURE
86	MEDICINE	ELKAYAM, URI MD	499500	01/06/05	ACTELION	STUDY TO ASSESS EFFICACY, SAFETY & TOLERABILITY OF TEZO-SENTAN
87	MEDICINE	ELKAYAM, URI MD	400230		FLOWMEDICA, INC	A PILOT STUDY OF THE RENAL & SYSTEMIC HEMODYNAMIC EFFECTS OF NESIRITIDE
88	MEDICINE	ELKAYAM, URI MD	400540		GLAXOSMITHKLINE	STUDY COMPARING THE EFFECTS OF CARVEDILOL MODIFIED RELEASE FORMULATION AND ATENOLOL
89	MEDICINE	ELKAYAM, URI MD	401170		SOLVAY PHARMACEUTICALS	STUDY TO EVALUATE THE EFFECTS OF DIFFERENT DOSES OF DAGLUTRIL
90	MEDICINE	ELKAYAM, URI MD	400735	06/29/05	NOVACARDIA, INC	DOSE-RANGING STUDY OF THE EFFECTS OF KW-3902 BOTH AS MONOTHERAPY & FLUROSEMIDE
91	MEDICINE	ELKAYAM, URI MD	401840	02/08/06	ABBOTT LABORATORIES	FENOFIBRIC ACID AND STATIN THERAPY FOR SUBJECTS WITH MIXED DYSLIPIDEMIA
92	MEDICINE	ELKAYAM, URI MD	561900	07/01/91	MULTIPLE SPONSOR PROJECT	VARIOUS SPONSOR PROJECTS SEE INDIVIDUAL SPONSOR FOLDERS
93	MEDICINE	ELKAYAM, URI MD	401855	02/08/06	ENCYSIVE PHARMACEUTICALS, INC	SITAXSENTAN SODIUM TO IMPROVE IMPAIRED EXERCISE TOLERANCE WITH DIASTOLIC HEART FAILURE
94	MEDICINE	ELKAYAM, URI MD	401845	02/08/06	ABBOTT LABORATORIES	COMBINATION THERAPY OF FENOFIBRIC ACID AND SIMVASTATIN STUDY
95	MEDICINE	ELKAYAM, URI MD	401735		ZEALAND PHARMA A/S	FLEXIBLE DOSE STUDY OF ZP120 ADMINISTERED AS I.V. INFUSION
96	MEDICINE	ELKAYAM, URI MD	496910		SCIOS INC.	FOLLOW-UP SERIAL INFUSIONS OF NATRECOR (NESIRITIDE) PATIENTS WITH HEART FAILURE
97	MEDICINE	ELKAYAM, URI MD	400650		ORQIS MEDICAL	MULTICENTER TRIAL OF THE ORQIS MEDICAL CRS FOR THE ENHANCED TREATMENT OF CHF
98	MEDICINE	ELKAYAM, URI MD	400305		TITAN PHARMACEUTICALS	STUDY OF DITPA IN PATIENTS W/T NYHA CLASS III AND IV CONGESTIVE HEART FAILURE
99	MEDICINE	ELKAYAM, URI MD	400225	02/14/05	OTSUKA AMERICA	STUDY TO EVALUATE THE LONG TERM EFFICACY OF ORAL TOLVAPTAN TABLETS
100	MEDICINE	ELKAYAM, URI MD	400805		SCIOS INC.	ASSESSMENT OF THE EFFECT OF INTRARENAL INFUSION OF NESIRITIDE ON RENAL BLOOD FLOW
101	MEDICINE	FONG, TSE-LING MD	401130	12/20/05	BRISTOL-MYERS SQUIBB	COMPARATIVE STUDY TO EVALUATE EARLY VIRAL LOAD REDUCTIONS & EXPLORATORY VIRAL KINETICS
102	MEDICINE	GEISELER, JAN MD	678800	06/26/97	CATO RESEARCH LTD	PHASE 2 STUDY OF THE SAFETY OF BOVINE IMMUNOGLOBULIN .....
103	MEDICINE	GITLITZ, BARBARA MD	489400	05/03/04	ELI LILLY AND COMPANY	PHASE III STUDY OF DELAYED VS. IMMEDIATE SECOND LINE THERAPY W/T DOCETAXEL
104	MEDICINE	GITLITZ, BARBARA MD	400750	08/18/05	ONCOGENEX TECHNOLOGIES INC	A PHASE 1-2 STUDY OF WEEKLY OGX-011 PLUS GEMCITABINE & CISPLATIN
105	MEDICINE	GITLITZ, BARBARA MD	400625	10/31/05	EMD PHARMACEUTICALS, INC	PHASE II, OPEN-LABEL CONTROLLED STUDY OF TWO DIFFERENT DOSES & SCHEDULES OF EMD 72000
106	MEDICINE	GITLITZ, BARBARA MD	400105	09/06/05	IMCLONE & BRISTOL-MYERS SQU	PHASE II TRIAL OF TWO DOSE SCHEDULES OF CARBOPLATIN/PACLITAXEL/CETUXIMAB
107	MEDICINE	GITLITZ, BARBARA MD	401245	08/30/05	WYETH-AYERST PHARMACEUTICALS	PHASE I, DOSE-ESCALATION STUDY OF ORAL SKI-606 IN SUBJECTS WITH MALIGNANT SOLID TUMORS
108	MEDICINE	GITLITZ, BARBARA MD	401405	10/13/05	GLAXOSMITHKLINE	PHASE I STUDY OF LAPATINIB IN COMBINATION WITH VINORELBINE IN SOLID TUMORS BREAST CANCER
109	MEDICINE	GITLITZ, BARBARA MD	401770	01/24/06	SANOFI-AVENTIS	AVE0005 (VEFG TRAP) ADMINISTERED IN PATIENTS WITH PLATINUM RESISTANT
110	MEDICINE	GITLITZ, BARBARA MD	401750	01/18/06	CELL THERAPEUTICS, INC	CT-2103 VS PACLITAXEL FOR TREATMENT OF WOMEN WITH CHEMOTHERAPY-NAIVE

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
111	MEDICINE	GITLITZ, BARBARA MD	401370		WYETH - AYERST RESEARCH	PHASE II STUDY OF HKI-272 FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
112	MEDICINE	GITLITZ, BARBARA MD	400021		MILLENNIUM PHARMACEUTICALS	A PHASE I/III TRIAL OF NEO-ADJUVANT DOCETAXEL & CISPLATIN PLUS WEEKLY BORTEZOM
113	MEDICINE	GITLITZ, BARBARA MD	400020		AVENTIS PHARMACEUTICALS	A PHASE I/III TRIAL OF NEO-ADJUVANT DOCETAXEL & CISPLATIN PLUS WEEKLY BORTEZOM
114	MEDICINE	GITLITZ, BARBARA MD	400765		GENENTECH INC	PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY OF BEVACIZUMAB
115	MEDICINE	GITLITZ, BARBARA MD	404500	12/07/04	SANOFI PHARMACEUTICALS INC	PHASE II TRIAL OF TAXOTERE & OXALIPLATIN COMBINATION CHEMO-THERAPY IN SQUAMOUS CELL
116	MEDICINE	GITLITZ, BARBARA MD	489000	03/29/04	WYETH-AYERST PHARMACEUTICALS	PHASE 2 STUDY OF MAC-321 ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT
117	MEDICINE	GITLITZ, BARBARA MD	493100	06/18/04	CELL THERAPEUTICS, INC	CT 2103 / CARBOPLATIN FOR FIRST LINE TREATMENT WITH ADVANCED (NSCLC)
118	MEDICINE	GOLDSTEIN, DAVID MD	672500	02/05/97	CARDIOLOGY TITHING ACCOUNT	CARDIOLOGY DIVISION ACCOUNT TITHING ACCOUNT
119	MEDICINE	HAYWOOD, JULIAN L MD	517000	07/01/91	LOS ANGELES COUNTY**DO NOT	CORONARY CARE TEACHING UNIT
120	MEDICINE	HAYWOOD, JULIAN L MD	648300	09/30/94	WHITE MEMORIAL MEDICAL CENTER	ACCORD STUDY
121	MEDICINE	HAYWOOD, JULIAN L MD	483300	12/16/03	WHITE MEMORIAL MEDICAL CENTER	WHITE MEMORIAL TEMPORARY ACCOUNT
122	MEDICINE	HESELTINE, PETER N MD	737700	07/01/91	VIRATEL	TOLERANCE & EFFICACY STUDY ON HTLV II VIRUS SUPPRESSION...
123	MEDICINE	HODGES, TONY MD	401300	11/30/04	HOFFMANN LA ROCHE INC	RELATIVE BIOAVAILABILITY STUDY OF GANCICLOVIR FROM THE PRO-DRUG VALGANCICLOVIR
124	MEDICINE	HODGES, TONY MD	400845	10/04/05	CHIRON CORPORATION	AN OPEN-LABEL TREATMENT USE OF (CYCLOSPORINE, USP) INHALATION SOLUTION (PULMINIQ)
125	MEDICINE	HODGES, TONY MD	839400	10/01/05	NDRI	CYSTIC FIBROSIS LUNG PROGRAM
126	MEDICINE	HODGES, TONY MD	401635	12/14/05	CADENCE PHARMACEUTICALS	ASSESS EFFICACY OF TOPICAL OXOMETAZINE 1.0% GEL IN PATIENTS UNDERGOING CATHETERIZATION
127	MEDICINE	HODGES, TONY MD	401330		CHIRON CORPORATION	EVALUATE THE SAFETY AND EFFICACY OF TIFACOGININ SUBJECTS WITH PNEUMONIA
128	MEDICINE	HODGES, TONY MD	400040	02/07/05	PFIZER INC	LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA
129	MEDICINE	HODIS, HOWARD MD	669710	12/11/96	PARKE-DAVIS	TROGLITAZONE AND ATHEROSCLEROSIS STUDY
130	MEDICINE	HOLTOM, PAUL D MD	495900	10/19/04	CUBIST PHARMACEUTICALS	IN VITRO STUDY OF BIOFILMS IN PROSTHETIC JOINT INFECTION MODELS WHEN TREATED
131	MEDICINE	HOLTOM, PAUL D MD	401560	11/14/05	PENINSULA PHARMACEUTICALS	STUDY OF DORIPENEM VERSUS PIPERACILLIN-TAZOBACTAM IN THE TREATMENT OF SKIN INFECTIONS
132	MEDICINE	HOLTOM, PAUL D MD	496000	10/19/04	CUBIST PHARMACEUTICALS	COMPARISON OF DAPTOMYCIN TO VANCOMYCIN FOR GRAM-POSITIVE ORGANISMS
133	MEDICINE	HOLTOM, PAUL D MD	401660	12/21/05	PFIZER INC	LINEZOLID (IV/ORAL) EFFICACY/SAFETY IN CHRONIC OSTEOMYELITIS
134	MEDICINE	HORWITZ, DAVID A MD	674300	04/09/97	RHEUMATOLOGY TITHING ACCOUNT	DIVISION OF RHEUMATOLOGY TITHING ACCOUNT
135	MEDICINE	IQBAL, SYMA MD	451500	10/01/01	AVENTIS PHARMACEUTICALS	STUDY OF STUDY OF DOCETAXEL ESCALATING DOSES EXISULINDAVENTIS PROTOCOL 19063.....
136	MEDICINE	IQBAL, SYMA MD	461100	06/26/02	TELIK, INC	TLK286 IN PLATINUM RESISTANT ADVANCED EPITHELIAL OVARIAN CANCER
137	MEDICINE	IQBAL, SYMA MD	489300	04/05/04	ELI LILLY AND COMPANY	PHASE II STUDY OF CAPECITABINE & GEMCITABINE IN PATIENTS WITH METASTATIC COLORECTAL CANCER
138	MEDICINE	IQBAL, SYMA MD	405010	10/28/05	ROCHE LABORATORIES, INC	PHASE II STUDY OF OXALIPLATIN XELODA, AND AVASTIN AS TREATMENT FOR PATIENTS
139	MEDICINE	IQBAL, SYMA MD	400655	04/19/05	AVENTIS PHARMACEUTICALS	A PILOT TRIAL OF GERMLINE POLYMORPHISMS AS PREDICTORS OF RESPONSE TO GEMCITABINE, DOCETAXEL
140	MEDICINE	IQBAL, SYMA MD	405510	05/23/05	ROCHE LABORATORIES, INC	PHASE II STUDY OF OXALIPLATIN & XELODA AS FIRST LINE TREATMENT METASTATIC

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
141	MEDICINE	IQBAL, SYMA MD	401210		PFIZER INC	RANDOMIZED PILOT STUDY OF THEACTIVATION OF THE HEMOSTATICPATHWAY BY FOLFIRI
142	MEDICINE	IQBAL, SYMA MD	405500	12/17/04	SANOFI PHARMACEUTICALS INC	PHASE II STUDY OF OXALIPLATIN& AND XELODA AS FIRST LINETREATMENT METASTATIC
143	MEDICINE	IQBAL, SYMA MD	400660	05/02/05	AVENTIS PHARMACEUTICALS	PHASE II STUDY OF CPT-11 INDOCETAXEL IN PATIENTS W/TMETASTATIC OR UNRESECTABLE GAS
144	MEDICINE	IQBAL, SYMA MD	495400	07/20/05	PFIZER INC	PILOT STUDY WITH CPT-11, 5-FU& LEUCOVORIN WITH OR WITHOUTFRAGMIN
145	MEDICINE	IQBAL, SYMA MD	405000	05/13/05	GENENTECH INC	PHASE II STUDY OF OXALIPLATINXELODA, AND AVASTIN ASTREATMENT FOR PATIENTS
146	MEDICINE	IQBAL, SYMA MD	438100	01/04/01	ALZA	OC-00-6 LIPOSOMAL DOXORUBICINAND WEEKLY DOCETAXEL
147	MEDICINE	IQBAL, SYMA MD	480900	11/05/03	PFIZER INC	PHASE II STUDY OF IRINOTECAN(CAMPTOSAR), CISPLATIN & CELE-BREX IN PATIENTS W/METASTATIC
148	MEDICINE	JONES, BRENDA E	464200	09/30/02	UNIV OF SOUTHERN CALIFORNIA	USC REBILLABLE ACCT
149	MEDICINE	KAPLOWITZ, NEIL MD	634100	09/02/92	GI/LIVER TITHING ACCOUNT	GI / LIVER DIVISION TITHINGACCOUNT
150	MEDICINE	KAPTEIN, ELAINE MD	401860	02/08/06	QUEST DIAGNOSTICS	CORTISOL STUDY
151	MEDICINE	KLINE, MICHAEL M MD	474200	05/14/03	TAP PHARMACEUTICALS PRODU	PPI VERSUS PLACEBO IN SEVEREFUNCTIONAL HEARTBURN
152	MEDICINE	LAINE, LOREN A	675400	04/28/97	SEARLE PHARMACEUTICALS	DAILY THERAPIES FOR THEEERADICATION OF HELICOBACTER..
153	MEDICINE	LAINE, LOREN A	400975	10/25/05	GIVEN IMAGIN LTD	EVALUATION OF THE PILLCAM ESOCAPSULE IN THE DETECTIONOF ESOPHAGEAL VARICES
154	MEDICINE	LAINE, LOREN A	401620	12/01/05	TAP PHARMACEUTICALS PRODU	EFFECT OF FREQUENT ORAL DOSINGVS. CONSTANT IV INFUSION OFPROTON PUMP INHIBITOR
155	MEDICINE	LARSEN, ROBERT A MD	921000	01/01/86	UNIV OF CA, SAN DIEGO	CALIFORNIA COLLABORATIVE AIDSTREATMENT GROUP
156	MEDICINE	LARSEN, ROBERT A MD	463400	08/26/02	MERCK & CO.,INC	IMMUNOGENICITY OF MRK ADENO-VIRUS SEROTYPE 5 VECTOR (MRKAD5) HUMAN IMMUNODEFICIENCY
157	MEDICINE	LARSEN, ROBERT A MD	400410	05/17/05	MERCK & CO.,INC	STUDY OF L-000900612 IN COMBI-NATION W/T AN OPTIMIZED BACK-GROUND THERAPY (OBT)
158	MEDICINE	LARSEN, ROBERT A MD	401240		Oxxon Therapeutics Inc.	PHASE I/II EVALUATION OFHETEROLOGOUS PRIMEBOOSTIMMUNOTHERAPY IN HIV-1 SUBJECT
159	MEDICINE	LARSEN, ROBERT A MD	401815	02/03/06	ABBOTT LABORATORIES	LOPINAVIR/RITONVIR (LPV/R)LIQUID VERSUS CAPSULES STUDY
160	MEDICINE	LARSEN, ROBERT A MD	401875	02/09/06	GILEAD SCIENCES, INC.	GS-9137 VERSUS ACOMPARATOR RITONAVIR-BOOTEDPROTEASE INHIBITOR (CPI/R)
161	MEDICINE	LARSEN, ROBERT A MD	446010	08/12/05	BOEHRINGER INGELHEIM	A RETROSPECTIVE STUDY TOCOMPARE ANTIVARAL EFFICACYOF NEVIRAPINE AND EFVIRENZ
162	MEDICINE	LARSEN, ROBERT A MD	406300	12/29/04	FUJISAWA HEALTHCARE, INC	A PHASE 3 STUDY OF MICA FUNGIN(FK463) VERSUS CASPOFUNGINAS ANTIFUNGAL TREATMENT
163	MEDICINE	LARSEN, ROBERT A MD	432910	05/11/04	UNIV OF MINNESOTA	PHASE III STUDY OF BIOLOGICAL& CLINICAL EFFICACY OF SUB-CUTANEOUS RECOMBINANT
164	MEDICINE	LARSEN, ROBERT A MD	478800	10/16/03	GILEAD SCIENCES, INC.	PHASE 3 ANTIRETROVIRAL-NAIVEHIV-1 INF. PTS. COMP TENOFOVIRDISOPROXIL AND EMTRICITABINE
165	MEDICINE	LARSEN, ROBERT A MD	921010	07/01/90	UNIVERSITY OF SO CALIFORNIA	SALARY REIMBURSEMENTNOT A TYPICAL PROJECTACTS LIKE SALARY PASS-THROUGH
166	MEDICINE	LENZ, HEINZ-JOS MD	454000	12/13/01	SANOFI PHARMACEUTICALS INC	OXALIPLATIN IN COMBINATIONWITH CONTINUOUS INFUSION 5-FUIN PATIENTS WITH COLORECTAL
167	MEDICINE	LENZ, HEINZ-JOS MD	489800	04/05/04	IMCLONE & BRISTOL-MYERS SQU	PHASE III STUDY OF IRINOTECANCETUXIMAB VS. IRINOTECAN ASSECOND LINE TREATMENT
168	MEDICINE	LENZ, HEINZ-JOS MD	404300	09/06/05	IMMUNEX CORPORATION	A PHASE 2 MULTICENTER SINGLEARM CLINICAL TRIAL OF ABX-EGFMONOTHERAPY IN SUBJECTS

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
169	MEDICINE	LENZ, HEINZ-JOS MD	498800	10/19/04	NOVARTIS PHARMACEUTICALS C	PHASE I/II STUDY OF CELEBREX &EPO906 IN PATIENTS W/TMETASTATIC COLORECTAL CANCER
170	MEDICINE	LENZ, HEINZ-JOS MD	490200	07/01/04	PFIZER INC	PHASE II STUDY OF SU011248 INPATIENTS W/T METASTIC COLOR-ECTAL CANCER
171	MEDICINE	LENZ, HEINZ-JOS MD	485500	03/08/04	ELI LILLY AND COMPANY	PHASE II TRIAL OF GEMCITABINEPLUS 5FU/LEUCOVORIN (FFG) VS.OXALIPLATIN PLUS 5FU
172	MEDICINE	LENZ, HEINZ-JOS MD	460000		NORTHWESTERN UNIVERSITY	IRINOTECAN AND CISPLATIN +/-TRASTUZUMAB HERCEPTIN IN PATIENTS W/ADVANCED UPPER
173	MEDICINE	LENZ, HEINZ-JOS MD	459700	05/15/02	MILLENNIUM PHARMACEUTICALS	PS-341 PLUS DOCETAXEL INTREATMENT-NAIVE OR PREVIOUSLYTREATED PATIENTS WITH ADVANCED
174	MEDICINE	LENZ, HEINZ-JOS MD	482100	11/21/03	NOVARTIS PHARMACEUTICALS C	PHASE III STUDY OF OXALIPLATIN5-FLUOROURACIL LEUCOVORINW/T PTK787/ZK 222584
175	MEDICINE	LENZ, HEINZ-JOS MD	482000	11/21/03	NOVARTIS PHARMACEUTICALS C	PHASE III STUDY IN PATIENTSW/T METASTATIC ADENOCARCINOMAOF THE COLON OR RECTUM
176	MEDICINE	LENZ, HEINZ-JOS MD	400620	10/03/05	CELMED BIOSCIENCES, INC	A PHASE I/II STUDY OF NB101ADMINISTERED INTRAVENOUSLY BYINFUSION IN AN EVERY SECOND WK
177	MEDICINE	LENZ, HEINZ-JOS MD	400555	05/31/05	TAIHO PHARMACEUTICAL CO., LT	PHASE 3 STUDY OF S-1 IN COM-BINATION WITH CISPLATIN COM-PARED AGAINST 5-FU IN
178	MEDICINE	LENZ, HEINZ-JOS MD	400745		TAIHO PHARMACEUTICAL CO., LT	PHASE 2 STUDY OF S-1 AS 2ND LINE THERAPY FOR PATIENTS W/TMETASTATIC PANCREATIC CANCER
179	MEDICINE	LENZ, HEINZ-JOS MD	499900	02/24/05	PFIZER INC	TREATMENT PROTOCOL FORPATIENTS CONTINUING FROMPRIOR SU011248 PROTOCOLS
180	MEDICINE	LENZ, HEINZ-JOS MD	495500	09/24/04	IMMUNEX CORPORATION	PHASE II TRIAL OF PANITUMUMABMONOTHERAPY IN SUJECTS W/TMETASTATIC COLORECTAL CANCER
181	MEDICINE	LENZ, HEINZ-JOS MD	495200	07/30/04	THERION BIOLOGICS CORPORAT	PHASE III STUDY OF PANVAC-VFIN COMBINATION W/T GM-CSFVERSUS BEST SUPPORTIVE CARE
182	MEDICINE	LENZ, HEINZ-JOS MD	402500	07/15/05	IMMUNEX CORPORATION	A COMPANION PROTOCOL FORBIOMARKER DEVELOPMENT & PHARMACOGENETIC ANALYSIS IN SUBJECTS
183	MEDICINE	LENZ, HEINZ-JOS MD	492700	06/23/04	ROCHE LABORATORIES, INC	PHASE III STUDY OF INTER-MITTENT ORAL CAPECITABINE
184	MEDICINE	LENZ, HEINZ-JOS MD	491000	10/24/05	ROCHE LABORATORIES, INC	PHASE III STUDY OF INTERMITTENDORAL CAPECITABINE IN COMBIN-ATION W/T INTRAVENOUS
185	MEDICINE	LENZ, HEINZ-JOS MD	401675	01/04/06	MERCK & CO.,INC	VORINOSTAT IISP STUDY
186	MEDICINE	LENZ, HEINZ-JOS MD	401625	12/07/05	EISAI AMERICA, INC.	
187	MEDICINE	LENZ, HEINZ-JOS MD	401870	02/09/06	IMCLONE SYSTEMS	BEVACIZUMAB IN COMBINATIONWITH CETUXIMAB IN IRINOTECAN-REFRACTORY COLORECTAL CANCER
188	MEDICINE	LENZ, HEINZ-JOS MD	401485	10/27/05	PFIZER INC	MOLECULAR PREDICTORS OFRESPONSE IN TUMOR PATIENTSTREATED WITH SU11248
189	MEDICINE	LENZ, HEINZ-JOS MD	401270	11/28/05	NOVARTIS PHARMACEUTICALS C	MULTIPLE POTENTIAL BIOMARKERSTESTED IN GENE EXPRESSION OFVEFGFR-1-3 & HIF-1A & LDH-A
190	MEDICINE	LENZ, HEINZ-JOS MD	408000	03/11/05	IMCLONE & BRISTOL-MYERS SQU	PHASE II STUDY OF ERBITUXIN PATIENTS WITH REFRACTORY EGFR-NEGATIVE METASTATIC COLOR
191	MEDICINE	LENZ, HEINZ-JOS MD	408900	06/13/05	PFIZER INC	PHASE II TRIAL OF NEOADJUVANTIN COMBINATION WITH INFUSIONAL5-FU, LEUCOVORIN (FOLFIRI)
192	MEDICINE	LENZ, HEINZ-JOS MD	405600	12/20/04	IMMUNO-DESIGNED MOLECULES	A PHASE I/II TRIAL OF VACCINA-TION W/T DENDRITOPHAGE (D )PULSED WITH MULTIPLE PEPTIDES
193	MEDICINE	LENZ, HEINZ-JOS MD	468200	01/27/03	IMCLONE SYSTEMS	STUDY OF ERBITUX (CETUXIMAB)IN PATIENTS WITH METASTATICCOLORECTAL CARCINOMA

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
194	MEDICINE	LENZ, HEINZ-JOS MD	468500	01/27/03	NOVARTIS PHARMACEUTICALS C	STUDY OF XELODA AND GLEEVEGIN PATIENTS WITH METASTATIC COLORECTAL CANCER
195	MEDICINE	LENZ, HEINZ-JOS MD	455200	01/17/02	BRISTOL-MYERS SQUIBB	IRINOTECAN (CAMPOTOSAR) AND PACLITAXEL (TAXOL) IN PATIENTS WITH ADENOCARCINOMA .....
196	MEDICINE	LENZ, HEINZ-JOS MD	474500	05/23/03	PFIZER INC	PHASE II STUDY OF EFFICACY & SAFETY OF SU011248 IN PATIENTS WITH ADVANCED UNRESECTABLE
197	MEDICINE	LEVINE, ALEXANDRA M MD	474000	06/06/03	AMGEN INC.	PHASE II STUDY OF PEGFILGRAS-TIM ADMINISTERED ON SAME DAY OR NEXT DAY OF R-CHOP CHEMO
198	MEDICINE	LEVINE, ALEXANDRA M MD	402800	05/11/05	OSI PHARMACEUTICALS, INC	A PILOT PHASE II TRIAL OF COMBINATION THERAPY W/ FLUDARABINE MITOXANTRONE
199	MEDICINE	LEVINE, ALEXANDRA M MD	401110		PHARMACYCLICS, INC	
200	MEDICINE	LEVINE, ALEXANDRA M MD	406000	12/14/04	CELL THERAPEUTICS, INC	PHASE III COMPARATIVE TRIAL PIXANTRONE (BBR 2778) VERSUS OTHER CHEMOTHERAPEUTIC AGENTS
201	MEDICINE	LEVINE, ALEXANDRA M MD	401335		BIOGEN IDEC	
202	MEDICINE	LEVINE, ALEXANDRA M MD	401320		PHARMACYCLICS, INC	MOTEXAFIN GADOLINIUM FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
203	MEDICINE	LEVINE, ALEXANDRA M MD	401280		PHARMACYCLICS, INC	PHASE II TRIAL OF METEXOFIN GADOLINIUM IN PATIENTS WITH LYMPHOMA
204	MEDICINE	LEVINE, ALEXANDRA M MD	407200		GENENTECH INC	THE NATIONAL LYMPHOCARE STUDY AN OBSERVATIONAL STUDY OF TREATMENT, OUTCOMES
205	MEDICINE	LEVINE, ALEXANDRA M MD	400175	07/05/05	BIOGEN IDEC	STUDY TO EVALUATE THE EFFECT OF RITUXIMAB (IDEC-102) ON PRIMARY HUMORAL RESPONSE
206	MEDICINE	LEVINE, ALEXANDRA M MD	401060		NOVARTIS PHARMACEUTICALS C	A PHASE II TRIAL OF IMATINIB MESYLATE (GLEEVEC) IN PATIENTS WITH HIV RELATED KAPOSIS SARCOMA
207	MEDICINE	LEVINE, ALEXANDRA M MD	478200	08/29/03	HEMATOLOGY TITHING ACCOUNT	DIVISION OF HEMATOLOGY TITHING ACCOUNT
208	MEDICINE	LEVINE, ALEXANDRA M MD	474300	05/29/03	ABBOTT LABORATORIES	PHASE II STUDY EVALUATING THE SAFETY & EFFICACY OF ABT-510 IN SUBJECTS W/ T REFRACTORY
209	MEDICINE	LEVINE, ALEXANDRA M MD	476700	08/07/03	ORTHO BIOTECH PRODUCTS, L.P	PHASE II STUDY OF LIPOSOMAL DOXORUBICIN (DOXIL) IN COMBINATION WITH RITUXAN
210	MEDICINE	LEVINE, ALEXANDRA M MD	476800		BIOCRIST PHARMACEUTICALS	PHASE I MULTICENTER STUDY OF INTRAVENOUS BCX-1777 IN PATIENTS W/ T REFRACTORY
211	MEDICINE	LIEBMAN, HOWARD MD	475000	06/16/03	GLAXOSMITHKLINE	HEPARIN INDUCED THROMBOCYTOPENIA (HIT) AFTER VASCULAR SURGERY INCIDENCE OF HEPARIN-PLATELET
212	MEDICINE	LIEBMAN, HOWARD MD	400135	10/17/05	GLAXOSMITHKLINE	STUDY OF SB 4971 15-GR, A THROMBOPOIETIN RECEPTOR AGONIST, ADMINISTERED
213	MEDICINE	LIEBMAN, HOWARD MD	400995	07/12/05	AMGEN INC.	AN OPEN LABEL STUDY EVALUATING THE SAFETY & EFFICACY OF LONG TERM DOSING OF AMG 531
214	MEDICINE	LIEBMAN, HOWARD MD	400790	08/01/05	AMGEN INC.	EFFECTS OF LONG-TERM DOSING OF AMG 531 ON BONE MARROW MORPHOLOGY IN THROMBOCYTOPENIC
215	MEDICINE	LIEBMAN, HOWARD MD	400580	12/13/05	GLAXOSMITHKLINE	PHASE II STUDY OF A THROMBO-POIETIN RECEPTOR AGONIST SB-497115-GR
216	MEDICINE	LIEBMAN, HOWARD MD	404800	04/22/05	AMGEN INC.	STUDY OF AMG 531 TREATMENT OF THROMBOCYTOPENIC SUBJECTS WITH IMMUNE (IDIOPATHIC)
217	MEDICINE	LIEBMAN, HOWARD MD	484900	03/15/04	ILEX ONCOLOGY	TREATMENT OF REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA W/ T ALEMTUZUMAB (CAMPATH-1H)
218	MEDICINE	LIEBMAN, HOWARD MD	402400	04/22/05	AMGEN INC.	STUDY EVALUATING THE EFFICACY & SAFETY OF AMG 531 TREATMENT OF THROMBOCYTOPENIC SUBJECTS
219	MEDICINE	LINDSAY, KAREN L MD	455000	01/10/02	PRINCIPAL INVESTIGATOR	EDUCATIONAL ACCOUNT (PIHC)
220	MEDICINE	LINDSAY, KAREN L MD	400325	03/29/05	IDENIX PHARMACEUTICALS	PHASE IIB OF NM283 & THE COMBINATION OF PEGYLATED INTERFERON PLUS NM283

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
221	MEDICINE	LINDSAY, KAREN L MD	401215	01/23/06	VALEANT RESEARCH & DEVELOP	ANALYSIS OF HEPATITIS C VIRALKINETICS AND VIRAMIDINEPHARMACOKINETICS
222	MEDICINE	LINDSAY, KAREN L MD	401490	10/28/05	GLAXOSMITHKLINE	PHASE II PARALLEL DOSE-RANGINGSTUDY TO ASSES THE ANTIFIBROTIACIVITY OF GI262570 IN HEP C
223	MEDICINE	LINDSAY, KAREN L MD	401040	11/14/05	ROCHE LABORATORIES, INC	STUDY OF PEGASYS® PLUS COPEGUSIN TREATMENT-NAÏVE LATINOPATIENTS WITH CHRONIC
224	MEDICINE	LINDSAY, KAREN L MD	400200	03/09/05	RIBAPHARM	SAFETY & EFFICACY OF VIRA-MIDINE TO RIBAVIRIN IN TREAT-MENT-NAIVE PATIENTS
225	MEDICINE	LINDSAY, KAREN L MD	438200	01/11/01	SCHERING PLOUGH RESEARCH	SPRI CLINICALTRIAL FOR THETREATMENT OF CHRONIC ...
226	MEDICINE	LINDSAY, KAREN L MD	490900	07/26/04	RIBAPHARM	STUDY TO COMPARE SAFETY &EFFICACY OF VIRAMIDINE TORIBAVIRIN
227	MEDICINE	LINDSAY, KAREN L MD	487600	03/18/04	ROCHE LABORATORIES, INC	STUDY EXAMINING THE EFFECTS OFDURATION OF TREATMENT & HIGHINDUCTION DOSE OF PEGASYS
228	MEDICINE	LIU, MING MD	497100	11/01/04	MEDTRONIC	MEDTRONIC DRIVER ACUTEPERFORMANCE REGISTRY STUDY
229	MEDICINE	LIU, MING MD	401355		DUKE CLINICAL RESEARCH INST.	THE CRUSADE NATIONAL QUALITY IMPROVEMENT INITIATIVE
230	MEDICINE	LIU, MING MD	401565	11/15/05	SANOFI-AVENTIS	STUDY OF HEXADECASACCHARIDEINCLUDING ACTIVE CONTROL INPATIENTS WITH UNSTABLE ANGINA
231	MEDICINE	LIU, MING MD	400775		MILLENNIUM PHARMACEUTICALS	EARLY GLYCOPROTEIN IIB/IIIAINHIBITION IN NON-ST-SEGMENTELEVATION ACUTE CORONARY SYNDR
232	MEDICINE	LIU, MING MD	404100	04/11/05	THE MEDICINES COMPANY	THE ACUITY TRIAL: COMPARISONOF ANGIOMAX (BIVALIRUDIN)VERSUS LOVENOX (ENOXAPARIN)
233	MEDICINE	LU, SHELLY C	626800	10/19/91	UNITED LIVER ASSOCIATION	MOLECULAR BIOLOGY OF GSHSYNTHESIS
234	MEDICINE	MADKOUR, HOSAMELDI H	471000	04/07/03	ORTHO BIOTECH PRODUCTS, L.P	CORRECTION OF HEMOGLOBIN& OUTCOMES IN RENALINSUFFICIENCY (CHOIR)
235	MEDICINE	MATHUR, RUCHI	401180	12/09/05	PFIZER INC	A PHASE 3BMULTICENTER PILOT TRIALEFFECTS OF FORCED EXUBERA
236	MEDICINE	MEHRA, ANILKUMAR MD	444900	04/09/01	INTERVENTIONAL THERAPIES, LL	ANGIORAD TM RADIATIONTHERAPY FOR IN-STENTRESTENOSIS INTRA CORONARIES II
237	MEDICINE	MEHRA, ANILKUMAR MD	400755	06/13/05	SANOFI PHARMACEUTICALS INC	AN INTERNATIONAL STUDY OFFONDAPARINUX SODIUM VS. CONT-ROL THERAPY & GLUCOSE-INSULIN-
238	MEDICINE	MEHRA, ANILKUMAR MD	400855	07/21/05	ARGINOX PHARMACEUTICALS	PHASE III STUDY TO ASSESSSAFETY & EFFICACY OF NITRICACID SYNTHASE INHIBITION
239	MEDICINE	MEHRA, ANILKUMAR MD	400095	07/08/05	PROCTER & GAMBLE	STUDY OF PEXELIZUMAB INPATIENTS WITH ACUTE MYOCARDIALINFARCTION
240	MEDICINE	MEHRA, ANILKUMAR MD	401055		CV THERAPEUTICS	CLINICAL TRIAL TO EVALUATETHE EFFICACY & SAFETY OFRANOLAZINE VERSUS PLACEBO
241	MEDICINE	MEHRA, ANILKUMAR MD	463500	08/26/02	AVENTIS PHARMACEUTICALS	STUDY IN PATIENTS PRESENTINGWITH ACUTE CORONARYSYNDROMES - SYNERGY
242	MEDICINE	MOHRBACHER, ANN MD	497800	01/27/05	MILLENNIUM PHARMACEUTICALS	REPEAT DOSE PHARMACOKINETICS& PHARMACODYNAMICS OFBORTEZOMIB
243	MEDICINE	MOHRBACHER, ANN MD	406800	08/01/05	ORTHO BIOTECH PRODUCTS, L.P	TRIAL COMPARING THALIDOMIDEPLUS DEXAMETHASONE (THAL/DEX)VERSUS DOXIL®
244	MEDICINE	MOHRBACHER, ANN MD	400570	05/13/05	JOHNSON & JOHNSON	STUDY OF DOXIL®/CAELYX®AND VELCADETM OR VELCADE MONO-THERAPY
245	MEDICINE	MOHRBACHER, ANN MD	401380	10/10/05	MILLENNIUM PHARMACEUTICALS	PHASE II TRIAL OF FLUDARABINEVELCADE AND RITUXAN (FVR) INLOW GRADE LYMPHOMA AND CLL
246	MEDICINE	MOHRBACHER, ANN MD	400485	04/25/05	FAVRILLE, INC	PHASE III TRIAL OF FAVLD ANDGM-CSF VERSUS PLACEBO ANDGM-CSF FOLLOWING RITUXIMAB
247	MEDICINE	MOHRBACHER, ANN MD	492200	09/20/04	SPECTRUM PHARMACEUTICALS	PHASE II STUDY OF ELSAMITRUCIN(SPP 28090) IN PATIENTS W/TNON-HODGKIN'S LYMPHOMA
248	MEDICINE	NIDEN, ALBERT H MD	488700	03/29/04	WYETH-AYERST PHARMACEUTIC	STUDY OF ETANERCEPT IN PATIENTW/T IDIOPATHIC PULMONARYFIBROSIS (IPF)
249	MEDICINE	O'DAY, STEVEN MD	408820		CHIRON CORPORATION	PHASE II STUDY INDUCTIONTEMOZOLOMIDE CONCURRENT BIO-CHEMOTHERAPY

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
250	MEDICINE	PETERS HARMEL, ANNE M	475300	09/03/03	PFIZER INC	ONE-YEAR, THREE-ARM STUDY COMPARING EXUBERA VS. AVANDIAAS ADD-ON THERAPY VS. EXUBERA
251	MEDICINE	PINSKI, JACEK MD	491100	09/16/04	XANTHUS LIFE SCIENCES	DOSE DEFINING STUDY OF NAT2 PHENOTYPE-BASED DOSING REGIMEN OF INTRAVENOUS AMONAFIDE
252	MEDICINE	PINSKI, JACEK MD	400810		CELL GENESYS, INC	STUDY OF DOCETAXEL IN COMBINATION WITH CG1940 AND CG8711 VERSUS DOCETAXEL AND PREDNISON
253	MEDICINE	PINSKI, JACEK MD	401515	11/03/05	SANOPI-AVENTIS	A PHASE I/II TRIAL OF OXALIPLA AND PEMETREXED IN HORMONE REFRACTORY PROSTATE CANCER
254	MEDICINE	QUINN, DAVID MD	469800	02/24/03	ANTIGENICS, INC.	ADJUVANT ONCOPHAGE VERSUS OBSERVATION IN PATIENTS W/HIGH RISK OF RECURRENCE AFTER SURGI
255	MEDICINE	QUINN, DAVID MD	400005	03/21/05	HYBRIDON, INC	PHASE II STUDY OF TWO DOSE LEVELS OF IMOXINE™ (HYB2055 FOR INJECTION)
256	MEDICINE	QUINN, DAVID MD	494700	10/04/04	BAYER CORPORATION	PHASE III STUDY OF BAY-43-9006 IN PATIENTS W/T UNRESECTABLE METASTATIC RENAL CELL CANCER
257	MEDICINE	QUINN, DAVID MD	403400	12/03/04	SANOPI PHARMACEUTICALS INC	PHASE II STUDY OF GEMCITABINE OXALIPLATIN AND PACLITAXEL IN PATIENTS W/T REFRACTORY GERM
258	MEDICINE	QUINN, DAVID MD	469900	02/21/03	CELL THERAPEUTICS, INC	XYOTAX (CT-2103) VS DOCETAXEL FOR THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER
259	MEDICINE	QUINN, DAVID MD	400070		ASTRA ZENECA PHARMACEUTICALS	A PHASE II TRIAL OF ZD 1839 (IRESSA) IN PATIENTS WITH NON-RESECTABLE ADRENOCORTICAL
260	MEDICINE	QUINN, DAVID MD	401465	10/20/05	ASTELLA PHARMA US, INC	PHASE II, STUDY OF YM155 IN SUBJECTS WITH (HRPC) PRIOR CHEMOTHERAPY REGIMEN
261	MEDICINE	QUINN, DAVID MD	401195		CHIRON CORPORATION	A PHASE 1 TRIAL OF ALDESLEUKIN ADMINISTERED TO SUBJECTS WITH METASTATIC RENAL CELL CARCINOM
262	MEDICINE	QUINN, DAVID MD	408700	01/11/05	ARIAD	A PHASE II STUDY OF AP23573 AN MTOR INHIBITOR, IN PATIENTS WITH ADVANCED SARCOMA
263	MEDICINE	QUINN, DAVID MD	400710	08/29/05	PHARMION CORPORATION	TINZAPARIN FOR PRIMARY TREATMENT & EXTENDED SECONDARY PROPHYLAXIS OF VENOUS
264	MEDICINE	QUINN, DAVID MD	400785	06/20/05	AVENTIS PHARMACEUTICALS	A PHASE II STUDY OF BORTEZOMIB (VELCADE, PS-341) & DOCETAXEL IN PATIENTS WITH HORMONE
265	MEDICINE	QUINN, DAVID MD	400545	07/05/05	OREGON HEALTH SCIENCES	PHASE II STUDY OF DN-101 (HIGH DOSE PULSE CALCITRIOL) ANDROGEN-INDEPENDENT PROSTATE
266	MEDICINE	QUINN, DAVID MD	400140		MILLENNIUM PHARMACEUTICALS	PHASE I TRIAL OF PS341 & BEVACIZUMAB IN PATIENTS W/T ADVANCED OR RECURRENT RENAL
267	MEDICINE	QUINN, DAVID MD	401090		BAYER CORPORATION	STUDY TO PROVIDE SORAFENIB TO PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
268	MEDICINE	QUINN, DAVID MD	400470	05/19/05	JOHNSON & JOHNSON	STUDY TO ASSESS THE EFFECT OF OMEPRAZOLE ADMINISTRATION ON PHARMACOKINETICS OF VELCADE
269	MEDICINE	RAHIMTOOLA, SHAHBUDIN	594000	03/11/88	PFIZER INC	EFFICACY & SAFTY OF NIFEDIDINE GITS VS PROPRANOLOL LA
270	MEDICINE	RAO, ADUPA P MD	497500	02/22/05	GENENTECH INC	EPIDEMIOLOGIC STUDY OF CYSTIC FIBROSIS
271	MEDICINE	RAO, ADUPA P MD	497600	11/29/04	C.R. BARD, INC.	TRIAL OF THE BARD SILVER COATED ENDOTRACHEAL TUBE TO REDUCE VENTILATOR
272	MEDICINE	REA, THOMAS H	468700	01/30/03	CELGENE CORPORATION	EDUCATIONAL ACCOUNT
273	MEDICINE	REA, THOMAS H	401350		CELGENE CORPORATION	LENALIDOMIDE STUDY
274	MEDICINE	RUNNEGAR, MARIA MD	672300	01/31/97	UNIVERSITY OF ILLINOIS	UNIV OF ILLINOIS FOUNDATION
275	MEDICINE	RUSSELL, CHRISTY A	470800	03/10/03	BREAST CANCER INTERNATIONAL	COMPARING DOXORUBICIN & CYCLO-PHOSPHAMIDE FOLLOWED BY DOCE-TAXEL W/DOXORUBICIN & CYCLOPHO

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
276	MEDICINE	RUSSELL, CHRISTY A	474400	05/23/03	BREAST CANCER INTERNATIONAL	PHASE III COMPARING DOCETAXELIN COMBINATION W/T DOXORUBICIN& CYCLOPHOSPHAMIDE (TAC)
277	MEDICINE	RUSSELL, CHRISTY A	461300	07/08/02	ELI LILLY AND COMPANY	GEMCITABINE + DOCETAXELVS DOCETAXEL + CEPACITABINEIN METASTATIC BREAST CANCER
278	MEDICINE	RUSSELL, CHRISTY A	497700	06/29/05	CITY OF HOPE	PHASE I/II TRIAL OF ZD 1839(IRESSA), TRASTUZUMAB (HER-CEPTIN) & DOCETAXEL
279	MEDICINE	RUSSELL, CHRISTY A	490600	08/30/04	GLAXOSMITHKLINE	PHASE II STUDY OF ORAL GW572016 AS SINGLE AGENT THERAPY
280	MEDICINE	SARMA, RADHA J MD	403800	04/13/05	NOVARTIS PHARMACEUTICALS C	AVOIDING CARDIOVASCULAR EVENTSTHROUGH COMBINATION THERAPY INPATIENTS LIVING WITH SYSTOLIC
281	MEDICINE	SARMA, RADHA J MD	401775	01/30/06	MEDTAP INSTITUTE	TIME AND MOTION STUDY TOEVALUATE THE COSTS OFCARDIOVERSION FOR FIBRILLATION
282	MEDICINE	SARMA, RADHA J MD	403300	02/02/05	TAKEDA	STUDY IN SUBJECTS WITH TYPE 2DIABETES MELLITUS COMPARINGEFFECTS OF PIOGLITAZONE
283	MEDICINE	SATTLER, FRED R MD	478500	04/01/04	INFECTIOUS DISEASE TITHING	INFECTIOUS DISEASES DIVISIONACCOUNT / TITHING ACCOUNT
284	MEDICINE	SATTLER, FRED R MD	400720	10/11/05	SOLVAY PHARMACEUTICALS	EFFECTS OF ANDROGEN THERAPYON CARBOHYDRATE & LIPID META-BOLISM IN ELDERLY MEN
285	MEDICINE	SAXON, LESLIE MD	489600	04/05/04	GUIDANT	CONTAK RENEWAL 3 AVT DEVICESTUDY
286	MEDICINE	SAXON, LESLIE MD	400480	04/21/05	GUIDANT	AUTOMATIC DEFIBRILLATOR IMPLA-NTATION TRIAL W/T CARDIAC RES-YNCHRONIZATION THERAPY
287	MEDICINE	SHAPIRO, SHELLEY MD	470010	07/10/03	PFIZER INC	LONG-TERM EXTENSION STUDY TOASSESS SAFETY & TOLERATION OFSUBJECTS OPTIMISED
288	MEDICINE	SHAPIRO, SHELLEY MD	400115		INO THERAPEUTICS	DOSE RESPONSE OF PULSED NITRIC OXIDE IN ADULTS W/TPRIMARY PULMONARY HYPERTENSION
289	MEDICINE	SHAPIRO, SHELLEY MD	494900	08/02/04	MYOGEN INC.	LONG TERM STUDY OF AMBRISENTANIN PULMONARY ARTERIAL HYPER-TENSION SUBJECTS
290	MEDICINE	SHAPIRO, SHELLEY MD	484200	01/12/04	ENCYSIVE PHARMACEUTICALS, IN	LONG TERM OPEN-LABEL STUDYTO EVALUATE SAFETY OF SITAX-SENTAN SODIUM TREATMENT
291	MEDICINE	SHAPIRO, SHELLEY MD	486510	03/30/05	PFIZER INC	OPEN-LABEL EXTENSION STUDYOF ORAL SILDENAFIL FORPATIENTS WHO COMPLETE A1481141
292	MEDICINE	SHAPIRO, SHELLEY MD	486700	04/06/04	MYOGEN INC.	ARIES-1, PHASE III STUDY OFAMBRISENTAN IN SUBJECTS W/TPULMONARY ARTERIAL
293	MEDICINE	SHAPIRO, SHELLEY MD	486500	04/01/04	PFIZER INC	SUBJECT OPTIMISED DOSE OFSILDENAFIL (20,40 OR 80 MGSILDENAFIL TID)
294	MEDICINE	SHAPIRO, SHELLEY MD	484110	02/09/04	ENCYSIVE PHARMACEUTICALS, IN	OPEN-LABEL STUDY TO EVALUATELONG-TERM SAFETY SITAXSENTANSODIUM TREATMENT W/T BOSENTAN
295	MEDICINE	SHARMA, OM P MD	486400	06/01/04	CENTOCOR, INC.	TRIAL EVALUATING SAFETY &EFFICACY OF INFLIXIMAB (REMIC-ADE) IN SUBJECTS W/T CHRONIC
296	MEDICINE	SINGER, PETER A MD	401065		CEDARS-SINAI MEDICAL CENTER	DOES SURGICAL DEBULKING OFFITUITARY ADENOMAS IMPROVERESPONSIVENESS TO OCTREOTIDE
297	MEDICINE	SMOGORZEWSKI, MIROSLA	499000	12/20/04	SHIRE US	PHASE IIIB STUDY ASSESSING ANEXTENDED DOSE RANGE OF LAN-THANUM CARBONATE
298	MEDICINE	SPENCER, CAROLE PHD	401865	02/09/06	AMGEN INC.	AMG 706 TO TREAT SUBJECTSWITH LOCALLY ADVANCED ORMETASTATIC THYROID CANCER
299	MEDICINE	SQUIRES, KATHLEEN MD	470600	03/10/03	ABBOTT LABORATORIES	COMPARTMENTAL STUDY OF KA-LETRA + STAVUDINE & LAMUVIDINEIN HIV-POSITIVE ANTIRETROVIRAL
300	MEDICINE	SQUIRES, KATHLEEN MD	484300	02/14/05	BOEHRINGER INGELHEIM	LONG-TERM OPEN-LABEL ROLLOVERTRIAL ASSESSING THE SAFETY &TOLERABILITY OF COMBINATION
301	MEDICINE	SQUIRES, KATHLEEN MD	487100	01/12/05	TIBOTEC PHARMACEUTICALS	PHASE II 48 WEEK TRIAL W/TTMC114/RTV IN 3-CLASS EX-PERIEENCED MULTI PI-EXPERIENCED

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
302	MEDICINE	SQUIRES, KATHLEEN MD	400930		INCYTE CORPORATION	A LONG-TERM OPEN-LABEL NONRANDOMIZED STUDY TO EVALUATE SAFETY OF 100 AND 200 MG REVER
303	MEDICINE	SQUIRES, KATHLEEN MD	496400	10/12/04	INCYTE CORPORATION	STUDY EXPLORING THE SAFETY, TOLERABILITY, & VIROLOGICAL EFFECT OF 50, 100, & 200
304	MEDICINE	SQUIRES, KATHLEEN MD	476300	07/21/03	BOEHRINGER INGELHEIM	TIPRANAVIR BOOSTED W/LOW-DOSE RITONAVIR (TPV/RTV) VS GENOTYPICALLY-DEFINED PROTEASE INHIB
305	MEDICINE	STOHL, WILLIAM MD	462700	08/13/02	HUMAN GENOME SCIENCES, INC.	PHASE I TO EVALUATE SAFETY LYMPHOSTAT-B SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
306	MEDICINE	STOHL, WILLIAM MD	490700	06/01/04	HUMAN GENOME SCIENCES, INC.	PHASE II STUDY TO EVALUATE SAFETY, TOLERABILITY, & EFFICACY LYMPHOSTAT B ANTIBODY
307	MEDICINE	STOHL, WILLIAM MD	400400	02/09/05	XENCOR INC	BAFF ANTAGONIST EXPERIMENTS ANIMAL STUDY
308	MEDICINE	STOHL, WILLIAM MD	490710	10/21/05	HUMAN GENOME SCIENCES, INC.	CONTINUATION TRIAL OF LYMPHOSTAT-B ANTIBODY IN SUBJECTS WITH RHEUMATOID ARTHRITIS
309	MEDICINE	STOHL, WILLIAM MD	400575	06/17/05	AMGEN INC.	STUDY OF OF AMG 623 FOLLOWING MULTI-DOSE ADMINISTRATION IN SUBJECTS W/T SYSTEMIC LUPUS
310	MEDICINE	STOHL, WILLIAM MD	401785	01/30/06	GENENTECH INC	STUDY TO EVALUATE RITUXIMABIN COMBINATION WITH (MTX) WITH ACTIVE RHEUMATOID ARTHRITIS
311	MEDICINE	STOHL, WILLIAM MD	401835	02/08/06	HUMAN GENOME SCIENCES, INC.	BLYS STUDY
312	MEDICINE	STOHL, WILLIAM MD	485910	10/27/05	HUMAN GENOME SCIENCES, INC.	CONTINUATION TRIAL OF LYMPHOST-B ANTIBODY IN SUBJECTS WITH LUPUS ERYTHEMATOSUS (SLE)
313	MEDICINE	STOHL, WILLIAM MD	409300	02/07/05	AMGEN INC.	STUDY TO EVALUATE THE SAFETY TOLERABILITY, PHARMACOKINETICS & PHARMACODYNAMICS OF AMG 623
314	MEDICINE	STOHL, WILLIAM MD	485900	02/06/04	HUMAN GENOME SCIENCES, INC.	PHASE II STUDY OF LYMPHOSTAT-B ANTIBODY (MONOCLONAL ANTI-BLYS ANTIBODY) IN SUBJECTS
315	MEDICINE	TULPULE, ANIL MD	457900	03/27/02	AMGEN INC.	PILOT TRIAL OF DARBEPOETIN -ALFA IN HIV SEROPOSITIVE PATIENTS WITH ANEMIA
316	MEDICINE	TULPULE, ANIL MD	492000	08/27/04	SALMEDIX, INC	PHASE II STUDY TO INVESTIGATE SAFETY & ACTIVITY OF SDX-105 (BENDAMUSTINE)
317	MEDICINE	TULPULE, ANIL MD	400160	04/01/05	MEDIMMUNE, INC.	A PHASE I STUDY TO EVALUATE MEDI-507 IN PATIENTS W/T CD2-POSITIVE CELL LYMPHOMA/LEUKEM
318	MEDICINE	TULPULE, ANIL MD	400795	07/05/05	Genmab	TRIAL OF HUMAX-CD4, A FULLY HUMAN MONOCLONAL ANTI-CD4 ANTIBODY, IN PATIENTS
319	MEDICINE	TULPULE, ANIL MD	400170	04/19/05	ORTHO BIOTECH PRODUCTS, L.P	PHASE II STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN (DOXIL®) WITH RITUXIMAB
320	MEDICINE	TULPULE, ANIL MD	400760		SALMEDIX, INC	PHASE III STUDY TO INVESTIGATE THE SAFETY & EFFICACY OF TREANDA™ (BENDAMUSTINE HCL)
321	MEDICINE	WEBER, JEFFREY MD	661000	01/31/96	ONCOLOGY TITHING ACCOUNT	DIVISION OF ONCOLOGY ACCOUNT TITHING ACCOUNT
322	MEDICINE	WEBER, JEFFREY MD	473800	05/07/03	MEDAREX INC	COMPARING MDX-010 ALONE OR IN COMBINATION W/DTIC IN TREATMENT OF PATIENTS W/CHEMOTHERAPY NAI
323	MEDICINE	WEBER, JEFFREY MD	401500	04/13/05	MEDAREX INC	STUDY COMPARING MDX010 MONO-THERAPY, MDX010 IN COMBINATION WITH A MELANOMA PEPTIDE
324	MEDICINE	WEBER, JEFFREY MD	487500	03/29/04	MEDAREX INC	OPEN LABEL PHARMACOKINETIC STUDY OF TRANSFECTOMA-DERIVED MDX-010
325	MEDICINE	WEBER, JEFFREY MD	400290	04/18/05	GLAXOSMITHKLINE	PHASE II STUDY EVALUATING THE ANTI-TUMOR ACTIVITY OF SB-485232
326	MEDICINE	WEBER, JEFFREY MD	401810	02/01/06	BRISTOL-MYERS SQUIBB	
327	MEDICINE	WEBER, JEFFREY MD	401445	08/31/05	BAYLOR COLLEGE OF MEDICINE	VACCINATION OF PATIENTS WITH STAGE IV MELANOMA WITH DENDRITIC CELLS GENERATED

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
328	MEDICINE	WEBER, JEFFREY MD	400195	06/20/05	AMPLIMED CORPORATION	A PHASE I/III TRIAL OF AMPLIMEX(IMEXON, INJ.) PLUS DACARBAZIN(DTIC) IN CHEMOTHERAPY NAIVE
329	MEDICINE	WEBER, JEFFREY MD	400190	06/22/05	ZYMOGENETICS	PHASE I STUDY OF RECOMBINANT HUMAN INTERLEUKIN-21 (RIL-21) IN SUBJECTS W/T METASTATIC
330	MEDICINE	WEBER, JEFFREY MD	408810		BERLEX LABORATORIES INC	PHASE II STUDY OF INDUCTION TEMOZOLOMIDE CONCURRENT BIO-CHEMOTHERAPY
331	MEDICINE	WEBER, JEFFREY MD	408800	10/27/05	CHIRON CORPORATION	PHASE II STUDY OF INDUCTION TEMOZOLOMIDE CONCURRENT BIO-CHEMOTHERAPY
332	MEDICINE	WEBER, JEFFREY MD	487200	05/13/04	COLEY PHARMACEUTICAL	PROMUNE (CPG 7909 INJECTION) CHEMOTHERAPY FOR THE TREATMENT OF STAGE III B/C MELANOMA
333	MEDICINE	WEBER, JEFFREY MD	489200	05/05/04	MEDAREX INC	EXTENDED DOSING STUDY OF MDX-010 IN COMBINATION W/T TYROSINASE/GP100/MART-1
334	MEDICINE	WEBER, JEFFREY MD	486000	02/09/04	ILEX PRODUCTS, INC.	PHASE II STUDY OF ILX651 ADMINISTERED INTRAVENOUSLY DAILY FOR 5 CONSECUTIVE DAYS
335	MEDICINE	WEBER, JEFFREY MD	451400	09/28/01	MEDAREX INC	AN OPEN-LABEL STUDY OF MDX-CTLA4 IN COMBINATION WITH TYROSINASE/GP100/MART-1
336	MEDICINE	WEITZ, ILENE C MD	400905	11/09/05	ALEXION PHARMACEUTICALS	SHEPHERD: SAFETY IN HEMOLYTIC PNH PATIENTS TREATED WITH ECULIZUMAB: A MULTI-CENTER
337	MEDICINE	WEITZ, ILENE C MD	409600	09/27/05	GLAXOSMITHKLINE	STUDY OF AN ORAL THROMBOPOIETIN RECEPTOR AGONIST (SB-497115-GR)
338	MEDICINE	YANG, ALLEN S MD	401125	07/28/05	METHYLGENE INC	A PHASE I/III STUDY OF MGCD0103 IN COMBINATION WITH AZACITIDINE IN PTS. W/T HIGH-RISK MYELODYS
339	MEDICINE	YANG, ALLEN S MD	401150		PHARMION CORPORATION	A PHASE I BIOLOGICAL STUDY OF AZACITIDINE (VIDAZA) IN HEMATOLOGIC MALIGNANCIES
340	MEDICINE	ZARCHY, THOMAS M MD	401470	10/21/05	TAP PHARMACEUTICALS PRODUCTS	
341	MEDICINE	ZARCHY, THOMAS M MD	401535	11/04/05	TAP PHARMACEUTICALS PRODUCTS	PHASE 3, OPEN-LABEL STUDY TO ASSESS LONG TERM SAFETY OF TAK-390MR
342	MEDICINE	ZARCHY, THOMAS M MD	401525	11/04/05	TAP PHARMACEUTICALS PRODUCTS	SAFETY OF TAK-390MR AND AN ACTIVE COMPARATOR, LANSOPRAZOLONE HEALING OF ESOPHAGITIS
343	MEDICINE	ZARCHY, THOMAS M MD	401530	11/04/05	TAP PHARMACEUTICALS PRODUCTS	EFFICACY OF TAK-390MR COMPARED TO PLACEBO IN MAINTENANCE OF HEALING IN SUBJECT WITH ESOPHAGITIS
344	MEDICINE	ZEIDLER, ADINA MD	488900	04/16/04	ASTRA ZENECA PHARMACEUTICALS	6-WEEK, COMPARATIVE STUDY OF ROSUVASTATIN & ATORVASTATIN TREATMENT OF HYPERCHOLESTEROLEMIA
345	MEDICINE	ZEIDLER, ADINA MD	400050	09/06/05	TAKEDA	PHASE II STUDY OF THREE DOSES OF TAK-128 IN SUBJECTS WITH MILD TO MODERATE DIABETIC NEUROPATHY
346	MEDICINE	ZEIDLER, ADINA MD	400051	12/15/05	TAKEDA	EVALUATE THE SAFETY OF LONG-TERM ADMINISTRATION OF TAK-128 IN SUBJECTS WITH DIABETIC NEUROPATHY
	<b>MEDICINE Count</b>	322				
347	NEUROLOGY	BANDARI, DANIEL	401035	12/09/05	FOREST LABORATORIES INC.	DOUBLE BLIND PLACEBO CONTROLLED PILOT TRIAL OF MEMANTINE FOR COGNITIVE IMPAIRMENT IN MS
348	NEUROLOGY	BEYDOUN, SAID R MD	463000	09/19/02	ELI LILLY AND COMPANY	TREATMENT FOR SYMPTOMATIC PERIPHERAL NEUROPATHY IN PATIENTS WITH DIABETES
349	NEUROLOGY	BEYDOUN, SAID R MD	492610	12/29/04	SCHWARZ BIOSCIENCES, INC.	FOLLOW-ON TRIAL TO ASSESS SAFETY AND EFFICACY OF SPM 927 SUBJECTS WITH PAINFUL DISTAL
350	NEUROLOGY	BEYDOUN, SAID R MD	406700	05/02/05	SCHWARZ BIOSCIENCES, INC.	GROUP TRIAL TO ASSESS THE EFFICACY AND SAFETY OF SPM 927 (200, 400, AND 600 MG/DAY)
351	NEUROLOGY	BEYDOUN, SAID R MD	401545	11/10/05	MEDPACE, INC.	DIABETIC NEUROPATHY STUDY
352	NEUROLOGY	BEYDOUN, SAID R MD	463100	09/19/02	ELI LILLY AND COMPANY	TREATMENT OF PERIPHERAL NEUROPATHY IN PATIENTS WITH DIABETES
353	NEUROLOGY	BEYDOUN, SAID R MD	492600	06/23/04	SCHWARZ BIOSCIENCES, INC.	TRIAL TO ASSESS EFFICACY & SAFETY OF 200, 400, & 600 MG OF SPM 927

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
354	NEUROLOGY	BURNETT, MARGARET MD	499600	11/15/04	BIOGEN IDEC	STUDY OF AVONEX COMPARED W/T AVONEX IN COMBINATION W/T ORAL METHOTREXATE
355	NEUROLOGY	CHUI, HELENA MD	480300	03/08/04	NEUROLOGY TITHING ACCOUNT	DEPARTMENT OF NEUROLOGY TITHING ACCOUNT
356	NEUROLOGY	HECK, CHRISTY MD	419500	07/12/99	PFIZER INC	PLACEBO-CONTROLLED TRIAL OF FARICEPT IN EPILEPSY
357	NEUROLOGY	HECK, CHRISTY MD	404400		ELEKTA INSTRUMENTS	
358	NEUROLOGY	HECK, CHRISTY MD	401550	11/11/05	CYBERONICS, INC.	TREATMENT WITH PHARMACOTHERAPY OR ADJUNCTIVE VAGUS NERVE STIMULATION THERAPY
359	NEUROLOGY	HUI, JENNIFER S MD	462900	09/09/02	UNIV OF ROCHESTER	ASSESS THE EFFICACY & SAFETY OF CEP-1347 IN PATIENTS WITH EARLY PARKINSON'S DISEASE
360	NEUROLOGY	HUI, JENNIFER S MD	403700	01/14/05	KYOWA PHARMACEUTICAL INC	12 WEEK STUDY TO EVALUATE OF 10, 20 AND 40 MG/D ORAL DOSES OF KW-6002 (ISTRADEFYLLINE)
361	NEUROLOGY	HUI, JENNIFER S MD	400700	07/26/05	NOVARTIS PHARMACEUTICALS C	EVALUATE EFFECTS OF STALEVOON MOTOR FUNCTIONS & QUALITY OF LIFE IN PATIENTS
362	NEUROLOGY	HUI, JENNIFER S MD	401205		GE HEALTHCARE	OPEN-LABEL, PHASE 2 TO ASSESS THE SAFETY AND EFFICACY OF 99M TC-NC100697 INJECTION
363	NEUROLOGY	HUI, JENNIFER S MD	407400	04/27/05	NOVARTIS PHARMACEUTICALS C	MULTI-CENTER STUDY TO EVALUATE THE EFFECT OF STALEVOON IN PATIENTS WITH PARKINSON'S
364	NEUROLOGY	HUI, JENNIFER S MD	403710	05/17/05	KYOWA PHARMACEUTICAL INC	A LONG-TERM STUDY WITH ORAL 20 OR 40 MG/D DOSES OF KW-6002 AS TREATMENT FOR PARKINSON'S
365	NEUROLOGY	KACHUCK, NORMAN J MD	479900	10/06/03	BIOGEN INC	GROUP DESIGN SAFETY STUDY OF NATALIZUMAB IN COMBINATION W/T GLATIRAMER ACETATE (GA)
366	NEUROLOGY	KACHUCK, NORMAN J MD	400205	05/25/05	ACORDA THERAPEUTICS, INC	21-WEEK, PARALLEL GROUP STUDY OF ORAL FAMPRIDINE-SR (10 MG B.I.D.)
367	NEUROLOGY	KACHUCK, NORMAN J MD	401650	12/15/05	TEVA NEUROSCIENCE	SYNERGY OF CONDITIONING USING A SPINGOSINE-PHOSPHATE AGONIST WITH GLATIRAMER ACETATE
368	NEUROLOGY	KACHUCK, NORMAN J MD	401255	08/31/05	ACORDA THERAPEUTICS, INC	EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN MS-F203 TRIAL
369	NEUROLOGY	KACHUCK, NORMAN J MD	459110		BIOGEN IDEC	MRI'S FOR UNIVERSITY OF CALIFORNIA IRVINE
370	NEUROLOGY	KACHUCK, NORMAN J MD	459100	04/15/02	BIOGEN INC	NATALIZUMAB WHEN ADDED TO AVONEX IN PATIENTS WITH RELAPSING/REMITTING MS
371	NEUROLOGY	KACHUCK, NORMAN J MD	467200	12/10/02	PEPGEN CORPORATION	PHASE II ORAL RECOMBINANT OVINE INTERFERON TAU DAILY IN PATIENTS WITH SCLEROSIS
372	NEUROLOGY	KACHUCK, NORMAN J MD	494600	09/14/04	BIOGEN IDEC	EXTENSION STUDY OF NATALIZUMAB IN SUBJECTS WITH MULTIPLE SCLEROSIS
373	NEUROLOGY	KACHUCK, NORMAN J MD	477710	09/01/04	ACORDA THERAPEUTICS, INC	OPEN LABEL EXTENSION STUDY OF ORAL FAMPRIDINE-SR IN SUBJECTS WITH MULTIPLE SCLEROSIS
374	NEUROLOGY	KACHUCK, NORMAN J MD	461700	09/11/02	BIOGEN INC	COMBINED MITOXANTRONE INDUCTION TREATMENT WORSENING MULTIPLE SCLEROSIS - CANTIMUS
375	NEUROLOGY	KALAYJIAN, LAURA	400185	08/16/05	MEDICAL COLLEGE OF GEORGIA	RETROSPECTIVE STUDY OF IN UTERO ANTI-EPILEPTIC DRUG EFFECTS ON NEURODEVELOPMENT
376	NEUROLOGY	KO, DAVID MD	424600	12/03/99	PARKE-DAVIS	PREGABALIN OPEN LABEL ADD ON TRIAL TO DETERMINE LONG TERM..
377	NEUROLOGY	KO, DAVID MD	400165	03/29/05	GLAXOSMITHKLINE	EVALUATION OF LAMICTAL EXTENDED-RELEASE ADJUNCTIVE THERAPY IN PATIENTS
378	NEUROLOGY	KO, DAVID MD	400585		EISAI AMERICA, INC.	STUDY OF E2007 GIVEN AS ADJUNCTIVE THERAPY IN PATIENTS REFRACTORY TO PARITAL SEIZURES
379	NEUROLOGY	KO, DAVID MD	401115		VALEANT RESEARCH & DEVELOP	PHASE 3 STUDY TO DETERMINE THE EFFICACY AND SAFETY OF RETIGABINE
380	NEUROLOGY	KO, DAVID MD	401085		SCHWARZ BIOSCIENCES, INC.	TRIAL TO INVESTIGATE THE SAFETY & TOLERABILITY OF INTRAVENOUS SPM 927
381	NEUROLOGY	KO, DAVID MD	474600	07/28/03	GLAXOSMITHKLINE	DOUBLE BLIND RANDOMIZED TRIAL OF COGNITIVE EFFECTS OF LAMICTAL VS. TOPIRAMATE
382	NEUROLOGY	KO, DAVID MD	401400	12/07/04	SCHWARZ BIOSCIENCES, INC.	INVESTIGATE THE EFFICACY & SAFETY OF SPM 927 AS ADJUNCTIVE THERAPY IN SUBJECTS

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
383	NEUROLOGY	KO, DAVID MD	472310	06/25/04	SCHWARZ BIOSCIENCES, INC.	OPEN LABEL EXTENSION TRIAL TO DETERMINE TOLERABILITY & EFFICACY LONG TERM ORAL SPM 927
384	NEUROLOGY	KO, DAVID MD	400320	03/18/05	GLAXOSMITHKLINE	EVALUATION OF LAMICTAL EXTENDER RELEASE ADJUNCTIVE THERAPY IN SUBJECTS W/T PARTIAL SEIZURES
385	NEUROLOGY	KO, DAVID MD	401410	10/05/05	SCHWARZ BIOSCIENCES, INC.	AN OPEN-LABEL EXTENSION TRIAL OF LONG-TERM ORAL SPM 927 IN PATIENTS WITH PARTIAL
386	NEUROLOGY	KO, DAVID MD	472300	04/21/03	SCHWARZ BIOSCIENCES, INC.	EFFICACY & SAFETY OF SPM 927 AS ADJUNCTIVE THERAPY SUBJECTS WITH PARTIAL SEIZURES
387	NEUROLOGY	KO, DAVID MD	426800	02/29/00	PARKE-DAVIS	SAFETY TRIAL IN PATIENTS WITH REFRACTORY EPILEPSY
388	NEUROLOGY	LEW, MARK F MD	417400	05/04/99	TEVA PHARMACEUTICALS USA	STUDY FOR THE SAFETY TOLERABILITY & CLINICAL...
389	NEUROLOGY	LEW, MARK F MD	407710	06/23/05	MERCK KGaA	PHASE III FOLLOW-UP STUDY TO INVESTIGATE THE LONG-TERM SAFETY & EFFICACY OF SARIZOTAN
390	NEUROLOGY	LEW, MARK F MD	407700	01/19/05	MERCK KGaA	PHASE III TRIAL TO EVALUATE OF SARIZOTAN HCL 1 MG B.I.D. IN PATIENTS WITH PARKINSON'S
391	NEUROLOGY	LEW, MARK F MD	401080	07/19/05	BIOMEASURE	PHASE III STUDY OF SAFETY & EFFICACY OF DYSPORT® FOR TREATMENT OF CERVICAL DYSTONIA
392	NEUROLOGY	LEW, MARK F MD	400315	08/01/05	BOEHRINGER INGELHEIM	OPHTHALMOLOGIC SAFETY STUDY OF PRAMIPEXOLE IR VERSUS ROPINIROLE IN EARLY PARKINSON'S
393	NEUROLOGY	LEW, MARK F MD	488100	04/02/04	GLAXOSMITHKLINE	PHASE III B STUDY TO ASSESS THE EFFECTIVENESS OF ROPINIROLE ADD-ON THERAPY TO L-DOPA
394	NEUROLOGY	LEW, MARK F MD	464600	01/27/03	SKYE PHARMA	ROPINIROLE CR TABLETS PATIENTS PARKINSON'S DISEASE PHASE 2 ROPINIROLE CR STUDY 167
395	NEUROLOGY	LEW, MARK F MD	459210	05/15/03	SCHWARZ / BIOSCIENCES	OPEN-LABEL EXTENSION TO ASSESS THE SAFETY OF LONG-TERM TREATMENT OF ROTIGOTINE CDS
396	NEUROLOGY	LEW, MARK F MD	448000	08/01/01	ELAN PHARMACEUTICALS	IMMUNOGENECITY STUDY OF MYOBLOC (NEUROBLOC, BOTULINUM TOXIN TYPE B) INJECTABLE ...
397	NEUROLOGY	LEW, MARK F MD	453200	11/29/01	PD VARIOUS ANNUAL DONATIONS	ANNUAL PD UPDATE
398	NEUROLOGY	LEW, MARK F MD	401081	12/02/05	BIOMEASURE	EXTENSION STUDY TODAYSPORT Y-47-52120-051
399	NEUROLOGY	LEW, MARK F MD	401360		TEVA PHARMACEUTICALS USA	PARALLEL-GROUP STUDY TO ASSESS RASAGILINE AS A DISEASE MODIFYING AGENT IN PARKINSON'S DISEASE
400	NEUROLOGY	LEW, MARK F MD	452200	11/01/01	TEVA PHARMACEUTICALS USA	AN ACTIVE EXTENSION OF THE TVP1012/ 133 PRESTO STUDY - ABI-NATIONAL , MULTICENTER.....
401	NEUROLOGY	PETZINGER, GISELLE MD	457610	04/11/03	CROMEDICA ,INC.	OPEN-LABEL EXTENSION TO ASSESS THE SAFETY OF LONG-TERM TREATMENT OF ROTIGOTINE CDS
402	NEUROLOGY	SAHAI-SRIVASTAVA, SOMA	409400		ORTHO-MCNEIL PHARMACEUTICALS	A DOUBLE-BLIND TRIAL COMPARING THE EFFICACY, TOLERABILITY & SAFETY OF ROPINIROLE CR TABLETS WITH PLACEBO IN PATIENTS WITH PARKINSON'S DISEASE
403	NEUROLOGY	SAHAI-SRIVASTAVA, SOMA	406600	12/29/04	GLAXOSMITHKLINE	SINGLE-ATTACK EVALUATION OF TREXIMA TABLETS VS PLACEBO ADMINISTERED DURING THE MILD
404	NEUROLOGY	SUNG, GENE MD	491800	11/09/04	BOEHRINGER INGELHEIM	PREVENTION REGIMEN FOR EFFECTIVELY AVOIDING SECOND STROKES
405	NEUROLOGY	WEINER, LESLIE MD	404700	10/11/05	GENENTECH INC	A PHASE II OF RITUXIMAB (MABTHERA /RITUXAN ) IN ADULTS WITH RELAPSING REMITTING
406	NEUROLOGY	WEINER, LESLIE MD	406400	01/07/05	ABBOTT LABORATORIES	A 24 WEEK STUDY OF THE HUMAN ANTI-IL-12 ANTIBODY ABT-874 IN SUBJECTS WITH MULTIPLE SCLEROSIS
407	NEUROLOGY	WEINER, LESLIE MD	406500	06/02/05	GENENTECH INC	A PHASE II/III STUDY OF RITUXIMAB IN ADULTS WITH PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS
	<b>NEUROLOGY Count</b>	61				
408	NEUROSURGERY	CHEN, THOMAS MD	495700	08/12/04	NEOPHARM, INC	PHASE III EVALUATION OF CON-VECTION ENHANCED DELIVERY OF IL13-PE38QQR

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
409	NEUROSURGERY	CHEN, THOMAS MD	492400	09/30/04	XENOVA BIOMEDIX LIMITED	PHASE III INTRATUMORAL / INTERSTITIAL THERAPY W/T TRANSMID
410	NEUROSURGERY	CHEN, THOMAS MD	400145	03/29/05	DEPUY SPINE	AN IN VITRO STUDY ON THEPOTENTIAL USE OF PLATELET CON-CENTRATE FOR BONE FUSION
411	NEUROSURGERY	CHEN, THOMAS MD	401580	11/18/05	NOVARTIS PHARMACEUTICALS C	STUDY TO COMPARE THE EFFICACYOF GLIVEC ADMINISTERED WITHHYDROXYUREA
412	NEUROSURGERY	GIANNOTTA, STEVEN L MD	838900	12/01/02	UNIV OF MICHIGAN	CFAAST SUBCONTRACT
413	NEUROSURGERY	GIANNOTTA, STEVEN L MD	838110	06/01/02	UNIV OF IOWA	SUB - ACCOUNT
414	NEUROSURGERY	LARSEN, DONALD MD	476510	04/27/05	MICRO VENTION, INC	MICROVENTION HYDROCOILEMBOLIC SYSTEM (HES)PHASE II
415	NEUROSURGERY	LIU, CHARLES MD	401165	11/22/05	ARCHUS ORTHOPEDICS	STUDY TO EVALUATE SAFETY ANDEFFECTIVENESS OF TOTAL FACETANTHROPLASTY IN SPINAL STENOSI
416	NEUROSURGERY	SAMUDRALA, SRINATH MD	466800	12/09/02	FZIOMED INC	OXIPLEX/SP GEL FOR THE RE-DUCTION OF PAIN & SYMPTOMSFOLLOWING LUMBAR DISC SURGERY
417	NEUROSURGERY	WANG, MICHAEL MD	400110	06/20/05	DEPUY SPINE	STUDY COMPARING HEALOS TOILIAC CREST AUTOGRAFT INA POSTEROLATERAL LUMBAR FUSION
418	NEUROSURGERY	WANG, MICHAEL MD	400695		CONFLUENT SURGICAL, INC.	STUDY TO COMPARE SPINALSEALANT SYSTEM AS AN ADJUNCTTO SUTURED DURAL REPAIR
	<b>NEUROSURGERY Count</b>	11				
419	OB/GYN	DI ZEREGA, GERE S MD	595900	06/14/88	DECATUR/FRP JOINT VENTURE	LEVELS OF FOLLICLE REGULATORYPROTEIN DURIN NORMAL MENSTRUAL
420	OB/GYN	GOODWIN, THOMAS M MD	401365	10/06/05	SUMMIT DOPPLER SYSTEMS	
421	OB/GYN	GOODWIN, THOMAS M MD	401805	02/01/06	HEALTH POINT, LTD.	
422	OB/GYN	JAIN, JOHN MD	457300	03/29/02	PHARMACIA & UPJOHN	CONTRACEPTION STUDY OFMEDROXYGESTERONE ACETATE(MPA 20MG)
423	OB/GYN	JAIN, JOHN MD	464500	01/02/03	ORGANON	EDOMETRIAL HISTOLOGICAL PRO-FILE CONJUGATED ESTROGEN MED-ROXYPROGESTERONE ACETATE
424	OB/GYN	JAIN, JOHN MD	404000	02/07/05	FERRING PHARMACEUTICALS	STUDY OF THREE DOSAGE STRENGTHOF PULSATILE GNRH ADMINISTEREDINTRAVENOUSLY OR SUBCUTANEOUSL
425	OB/GYN	JAIN, JOHN MD	405100	01/03/05	PFIZER INC	EDUCATIONAL GRANT
426	OB/GYN	JAIN, JOHN MD	746100	07/01/03	UNIVERSITY OF PENNSYLVANIA	TWO DOSE METHOTREXATE FORETOPIC PREGNANCYSUBONTRACT 5-35654-B
427	OB/GYN	JAIN, JOHN MD	401221	12/02/05	ATHENIUM PHARMACEUTICALS, L	SUB ACCOUNT FOR 401220STUDY TO ASSESS SERUM &ENDOMETRIAL LEVELS
428	OB/GYN	JAIN, JOHN MD	401220		ATHENIUM PHARMACEUTICALS, L	PILOT STUDY TO ASSESS SERUMAND ENDOMETRIAL LEVELS OFMIFEPRISTON
429	OB/GYN	JAIN, JOHN MD	400915	11/21/05	TAP PHARMACEUTICALS PRODU	PHASE I STUDY OF THE EFFECTSOFA SOPRISNIL ON OVARIANACTIVITY AND OVULATION
430	OB/GYN	JAIN, JOHN MD	400015	05/06/05	SERONO LABORATORIES, INC.	4 ARMS PHASE IIB STUDY TO DET-ERMINE AN EFFECTIVE MULTIPLE-DOSE OF ANASTROZOLE
431	OB/GYN	JAIN, JOHN MD	493500	10/28/04	DEPARTMENT OF OB/GYN	ACCOUNT TO REIMBURSEDANCO INVESTORS GROUP FOR10 GRAMS OF POWDER
432	OB/GYN	JAIN, JOHN MD	746200	07/01/03	UNIVERSITY OF PENNSYLVANIA	SERUM BANK FOR ASSESSMENTOF MARKERS FOR ETOPICPREGNANCY
433	OB/GYN	JAIN, JOHN MD	405400	03/22/05	BERLEX LABORATORIES INC	STUDY COMPARING A 2.2 MG 17?ESTRADIOL/0/69 MG LEVONORGESTRCOMBINATION TRANSDERMAL PATCH
434	OB/GYN	KJOS, SIRI L MD	657800	09/05/95	JUVENILE DIABETES FOUNDATIO	USE OF FETAL CRITERIA TOSELECT THERAPY FOR GESTATIONAL
435	OB/GYN	KLUTKE, JOHN MD	496800	11/02/04	BOSTON SCIENTIFIC CORPORATI	NON-SIGNIFICANT RISK STUDY TOEVALUATE MIDURETHRAL VAGINALTAPE PROCEDURE
436	OB/GYN	KLUTKE, JOHN MD	403500	12/09/04	MENTOR CORPORATION	STUDY ON TRANS-OBTURATOR TAPEURETHRAL SLING IN WOMEN WITHSTRESS URINARY INCONTINENCE
437	OB/GYN	KLUTKE, JOHN MD	409000	04/26/05	MEDAFOR, INC	A RESTING HEMOSTASIS INSURGICAL TRAUMA APPLICATIONS
438	OB/GYN	LIN, PAUL MD	424300	11/29/99	SMITHKLINE BEECHAM	PHASE I/II TRIAL OF TOPOTECAN/CISPLATIN GIVEN IN NOVEL...
439	OB/GYN	MCGREGOR, JAMES A MD	401175		KV PHARMACEUTICALS	GROUP STUDY COMPARINGCLINDAMYCIN PHOSPHATE 2%BUTOCONAZOLE NITRATE 2%

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
440	OB/GYN	MEZROW-SLEISENGER, GA	629600	03/25/92	I C I AMERICAS INC	TRIAL COMPARING 3.6 MG ZOLADEX THERAPY.....
441	OB/GYN	MILLER, DAVID A MD	400945	10/07/05	PROMEDDX, LLC	COLLECTION OF MATERNAL & UMBILICAL CORD BLOOD FOR THE DEVELOPMENT OF ASSAYS
442	OB/GYN	MISHELL, DANIEL R MD	596500	07/05/88	REBILLABLE SALARY ACCOUNT	ABOG ACCOUNT
443	OB/GYN	MISHELL, DANIEL R MD	746700	11/01/05	POPULATION COUNCIL	PROTOCOL 300
444	OB/GYN	MISHELL, DANIEL R MD	401800	11/01/04	TRANSSCAN MEDICAL, INC.	T-SCAN 2000 ED CLINICAL PROTOCOL
445	OB/GYN	MISHELL, DANIEL R MD	511010	07/01/91	OB/GYN TITHING ACCOUNT	OB/GYN RESIDENT FUND/ GYN TITHING ACCOUNT
446	OB/GYN	MISHELL, DANIEL R MD	421000	08/25/99	PROMEDDX, LLC	EVALUATION OF BIOMARKERS FOR THE DIAGNOSIS & MGMT OF CLINICAL DISEASE-1ST TRIMESTER PREG
447	OB/GYN	MISHELL, DANIEL R MD	400125	04/04/05	BERLEX LABORATORIES INC	STUDY TO INVESTIGATE THE SAFETY & EFFICACY OF A 4-PHASIC ORAL CONTRACEPTIVE SH T00658ID
448	OB/GYN	MUDERSPACH, LAILA I MD	444800	04/30/01	SMITHKLINE BEECHAM	INFUSION OF TOPOTECAN CONCURRENT WITH RADIATION ...
449	OB/GYN	MUDERSPACH, LAILA I MD	499700	02/17/05	ANGSTROM PHARMACEUTICALS	PHASE II TRIAL OF TWO DOSE LEVELS OF SUBCUTANEOUS A6IN PATIENTS W/T ASYMPTOMATIC
450	OB/GYN	MUDERSPACH, LAILA I MD	401630	12/09/05	GLAXOSMITHKLINE	
451	OB/GYN	NUCATOLA, DEBORAH L M	485400	02/05/04	DEPARTMENT OF OB/GYN	PILOT STUDY OF MIFEPRISTONE PREVENTION OF BREAKTHROUGH BLEEDING IN NEW STARTERS
452	OB/GYN	PAULSON, RICHARD J	400840	11/04/05	FERRING PHARMACEUTICALS	MULTI-CENTER, RANDOMIZED, STUDY OF A VAGINAL MICRONIZED PROGESTERONE TABLET
453	OB/GYN	RODGERS, KATHLEEN E	475800	07/10/03	UNIV OF SOUTHERN CALIFORNIA	REBILLABLE SALARY ACCOUNT
454	OB/GYN	ROMAN, LYNDIA D MD	740602	07/01/89	GYNECOLOGIC ONCOLOGY GROUP	PER CAPITA FUNDING AWARD
455	OB/GYN	ROMAN, LYNDIA D MD	838500	01/01/00	UNIVERSITY OF MISSISSIPPI MED	CONSORTIUM AGREEMENT
456	OB/GYN	ROMAN, LYNDIA D MD	466510	02/03/03	ELI LILLY AND COMPANY	WEEKLY DOCETAXEL IN COMB. W/ GEMCITABINE IN PLATINUM RESISTANT OVARIAN CANCER & PRIMARY
457	OB/GYN	ROMAN, LYNDIA D MD	401700	12/02/04	PROMEDDX, LLC	PMDX007 CLINICAL SPECIMEN COLLECTION STUDY - SOLID TUMOR
458	OB/GYN	ROMAN, LYNDIA D MD	401795	01/31/06	NOVARTIS PHARMACEUTICALS C	PHASE III TRIAL OF PATUPLONE (EPO906) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN
459	OB/GYN	ROMAN, LYNDIA D MD	401780	01/30/06	SANOVI-AVENTIS	A PILOT PHASE II STUDY EVALUATING THE COMBINATION OF FOXALIPLATIN AND DOCETAXEL
460	OB/GYN	ROMAN, LYNDIA D MD	407300	05/16/05	ALLOS THERAPEUTICS	PHASE I/II STUDY OF RSR13 ADMINISTERED TO PATIENTS RECEIVING A COURSE OF CISPLATIN
461	OB/GYN	ROMAN, LYNDIA D MD	491600	06/18/04	CELL THERAPEUTICS, INC	CT-203 / CARBOPLATIN FOR PATIENTS W/T STAGE III OR IV OVARIAN OR PRIMARY CANCER
462	OB/GYN	ROMAN, LYNDIA D MD	464100	10/07/02	GRANT LIFE SCIENCES	IMMUNOLOGICAL ASSAY FOR HUMAN PAPANOVIRUS (HPV), SUBJECTS WITH CERVICAL DISEASE
463	OB/GYN	ROMAN, LYNDIA D MD	471300	06/23/03	GLAXOSMITHKLINE	PHASE II, MULTICENTER TRIAL OF FOXIL & CONTINUOUS INFUSION OF TOPOTECAN AS SALVAGE THERAPY
464	OB/GYN	SHOUBE, DONNA MD	475100	06/16/03	MERCK & CO., INC	EFFECT OF RALOXIFENE ON HOT FLASHES IN HEALTHY POSTMENOPAUSAL WOMEN
465	OB/GYN	SHOUBE, DONNA MD	460300	06/03/02	ELI LILLY AND COMPANY	VASOMOTOR SYMPTOMS IN POST-MENOPAUSAL WOMEN RECEIVING COMBINATION RALOXIFENE & ORAL
466	OB/GYN	SHOUBE, DONNA MD	400025		LICORICE	EFFECTIVENESS OF LICORICE EXTRACT TREATMENT OF PERI AND POSTA PILOT TRIAL
467	OB/GYN	TEMPLEMAN, CLAIRE MD	472800	04/10/03	FZIOMED INC	OXIPLEX/AP GEL FOR THE REDUCTION OF POSTOPERATIVE ADHESION FOLLOWING LAPAROSCOPIC GYNECO
468	OB/GYN	TEMPLEMAN, CLAIRE MD	226500	06/02/03	HRA SEED GRANTS	A PILOT STUDY TO INVESTIGATE THE MOLECULAR PATHOLOGY OF ENDOMETRIOSIS

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
469	OB/GYN	TEMPLEMAN, CLAIRE MD	400920	11/09/05	FZIOMED INC	PIVOTAL CLINICAL TRIAL TO DETERMINE THE SAFETY AND EFF-ICACY OF OXIPLEX@/AP GEL
470	OB/GYN	URWITZ-LANE, REBECCA S	409200	12/06/05	PFIZER INC	EFFECT OF OXYBUTYNIN VERSUSESTROGEN-RELEASING VAGINALRING
471	OB/GYN	UZELAC, PETER S MD	227100	07/18/04	HRA SEED GRANTS	SEED GRANT -EVALUATION OF SERUMANDROGEN LEVELS
472	OB/GYN	YESSAIAN, ANNIE MD	408600		GLAXOSMITHKLINE	OPEN-LABEL, PHASE II,INTRAVENOWEEKLY TOPOTECAN IN SUBJECTS WITH ENDOMETRIAL CANCER
	<b>OB/GYN Count</b>	54				
473	OPHTHALMOLOGY	CHANG, TOM MD	401050		MEDTAP INSTITUTE	VALIDITY OF THE VFQ-25IN AGE-RELATED MACULARDEGENERATION
474	OPHTHALMOLOGY	CHANG, TOM MD	400875	08/01/05	ALLERGAN INC	TRIAL TO ASSESS THE SAFETY &EFFICACY OF 700UG & 350UG DE-XAMETHASONE POSTERIOR SEGMENT
475	OPHTHALMOLOGY	CHANG, TOM MD	407800	01/03/05	ALLERGAN INC	A SIX-MONTH, PHASE 3 TRIALOF 700 UG AND 350 UG DEXAMETHASONE POSTERIOR SEGMENT DRUG
476	OPHTHALMOLOGY	CHANG, TOM MD	401230		MEDTAP INSTITUTE	VALIDATION OF VISUAL FUNCTIONQUESITONNAIRE-25 PEOPLE WITH A RELATED MOCULAR DEGENERATION
477	OPHTHALMOLOGY	CHONG, LAWRENCE P MD	400860	09/01/05	SURMODICS, INC	HELICAL INTRAVITREAL TRIAM-CINOLONE IMPLANT
478	OPHTHALMOLOGY	FRANCIS, BRIAN MD	497000	10/04/04	HERMANN EYE FUND	COMPARISON OF BRINZOLAMIDEOPHTHALMIC SUSPENSION 1%& BRIMONIDINE TARTRATE
479	OPHTHALMOLOGY	FRANCIS, BRIAN MD	488400	11/05/04	LUMENIS INC	PROSPECTIVE, RANDOMIZEDCONTROLLED TRIAL COMPARINGTOPICAL MEDICAL THERAPY
480	OPHTHALMOLOGY	HUANG, DAVID PH.D	405900	12/22/04	CARL ZEISS MEDITEC, INC.	SPECIFIC AIM 1: DEVELOP AC-OCTBIOMETRY FOR INTRAOCULAR LENS SPECIFIC
481	OPHTHALMOLOGY	HUANG, DAVID PH.D	401820	02/07/06	OPTOVUE, INC.	AIM 2: DEVELOP AC-OCT
482	OPHTHALMOLOGY	HUMAYUN, MARK MD	458200	03/25/02	SECOND SIGHT , LLC	CHRONIC RETINAL STIMULATIONSYSTEM TO PROVIDE ELECTRICALSTIMULATION OF THE RETINA
483	OPHTHALMOLOGY	HUMAYUN, MARK MD	405200		SECOND SIGHT , LLC	CHRONIC AND ACUTE IMPLANTHUMAN CLINICAL TRIALS
484	OPHTHALMOLOGY	LIM, JENNIFER I MD	837800	08/01/98	JOHN HOPKINS UNIVERSITY	SOCA SUBCONTRACT
485	OPHTHALMOLOGY	LIM, JENNIFER I MD	450700	10/10/01	EYETECH PHARMACEUTICALS	INTRAVITREAL INJECTION OFEYE001 ANTI-VEGF PEGYLATEDAPTAMER GIVEN EVERY 6 WEEKS...
486	OPHTHALMOLOGY	LIM, JENNIFER I MD	839010	08/01/03	JOHNS HOPKINS UNIVERSITY	SOCA SUBCONTRACTPATIENT COSTS ACCOUNT
487	OPHTHALMOLOGY	LIM, JENNIFER I MD	408500		QLT INC.	PHASE II/III TRIAL TO STUDYOF PRESERVATIVE - FREETRIAMCINOLONE ACETONIDE
488	OPHTHALMOLOGY	LIM, JENNIFER I MD	401120	11/07/05	ACUITY PHARMACEUTICALS	PHASE II STUDY OF CAND5 FORINTRAVITREAL INJECTION FORTREATMENT SUBFOVCAI CHOROICAL
489	OPHTHALMOLOGY	LIM, JENNIFER I MD	400910		GENAERA CORPORATION	PHASE 3 STUDY OF SQUALAMINE LACTATE (MSI-1256F) FOR THETREATMENT OF SUBFOVEAL
490	OPHTHALMOLOGY	LIM, JENNIFER I MD	466700	12/05/02	QLT INC.	PHASE III STUDY OF THE EFFECTSVISUDYNE THERAPY IN OCCULTWITH NO CLASSIC SUBFOVEAL
491	OPHTHALMOLOGY	LIM, JENNIFER I MD	400150	04/22/05	EYETECH PHARMACEUTICALS	AN OPEN LABEL, NON-COM-PARATIVE PROTOCOL FOR USE OFINTRAVITREOUS PEGAPTANIB
492	OPHTHALMOLOGY	LIM, JENNIFER I MD	401231		MEDTAP INSTITUTE	VALIDATION OF VFQ-25 INPEOPLE WITH AGE-RELATEDMACULAR DEGENERATION
493	OPHTHALMOLOGY	LIM, JENNIFER I MD	839003	08/01/05	JOHNS HOPKINS UNIVERSITY	SOCA SUBAWARD
494	OPHTHALMOLOGY	MEALLET, MARIO A MD	490810	08/09/04	ASTRA ZENECA PHARMACEUTICA	EVALUATION OF CATARACTOGENICPOTENTIAL OF QUETIAPINE FUMA-RATE (SEROQUEL)
495	OPHTHALMOLOGY	MINCKLER, DONALD S MD	429900	06/07/00	ALLERGAN INC	PATIENTS WITH CHRONIC OPENANGLE GLAUCOMA AT RISK FOR
496	OPHTHALMOLOGY	MINCKLER, DONALD S MD	485000	01/20/04	EYE-DEAS LLC	APPLANATION TONOMETER
497	OPHTHALMOLOGY	MINCKLER, DONALD S MD	406100	03/03/05	ALLERGAN INC	MASKED HISTOLOGICAL EVALUATIONTRABECULAR MESHWORK SPECIMENS COLLECTED FROM TRABECULECTOMY

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
498	OPHTHALMOLOGY	RAO, NARSING A MD	401725	01/09/06	ALLERGAN INC	ASSESS DEX PS DDS IN TREATMENTOF NON-INFECTIOUS OCULARINFLAMMATION OF THE ANTERIOR
499	OPHTHALMOLOGY	RAO, NARSING A MD	401730	01/09/06	ALLERGAN INC	ASSESS DEX PS DDS IN TREATMENTOF OCULAR INFLAMMAITON OFTHE POSTERIOR SEGMENT
500	OPHTHALMOLOGY	SADDA, SRINIVAS R MD	472900	04/10/03	VISIONCARE OPHTHALMIC	VISIONCARE OPHTHALMIC TECH-NOLOGIES IMPLANTABLE MINIATURETELESCOPE (IMT) IN PATIENTS
501	OPHTHALMOLOGY	SADDA, SRINIVAS R MD	476900	09/10/03	GENENTECH INC	PHASE III, SHAM INJECTION CON-TROLLED STUDY OF THE EFFICACY& SAFETY OF RHUFABV2
502	OPHTHALMOLOGY	SADDA, SRINIVAS R MD	483800	03/18/04	GENENTECH INC	PHASE III, STUDY OF EFFICACY &SAFETY OF RHUFAB V2 COMPAREDTO VERTEPORFIN PHOTODYNAMIC
503	OPHTHALMOLOGY	SADDA, SRINIVAS R MD	483810		GENENTECH INC	EXTENSION STUDY TO EVALUATETHE SAFETY AND TOLERABILITYOF RANIBIZUMAB
504	OPHTHALMOLOGY	SADDA, SRINIVAS R MD	400560	07/05/05	EMMES CORPORATION	DOHENY IMAGE READING CENTERAREDS GEOGRAPHIC ATROPHYRESEARCH
505	OPHTHALMOLOGY	SADDA, SRINIVAS R MD	407900	07/07/05	OXIGENE	DOHENY IMAGE READING CENTERSTUDY
506	OPHTHALMOLOGY	SADDA, SRINIVAS R MD	400865	06/01/05	GENVEC, INC	DOSE ESCALATION STUDY OFADGVPEDF.11.D IN NEOVACULARAGE-RELATED DEGENERATION (AMD)
507	OPHTHALMOLOGY	SADDA, SRINIVAS R MD	401510	12/01/05	GENENTECH INC	STUDY TO EVALUATE THE SAFETYAND TOLERABILITY OF RANIBIZUMAIN SUBJECTS W/ (CNV)
508	OPHTHALMOLOGY	SADDA, SRINIVAS R MD	401570	11/17/05	GENVEC, INC	
	<b>OPHTHALMOLOGY Count</b>	36				
509	ORTHOPEDICS	LEE, JACKSON MD	460900		ORTHOVITA INC.	A SYNTHETIC CORTICAL BONEVOID FILLER TO BE SCREWAUGMENTATION
510	ORTHOPEDICS	PATZAKIS, MICHAEL J MD	485300	01/26/04	WYETH-AYERST PHARMACEUTIC	PHASE III STUDY EVALUATINGTIGECYCLINE & LINEZOLIDE SUB-JECTS W/T VANCOMYCIN-RESISTANT
511	ORTHOPEDICS	PATZAKIS, MICHAEL J MD	400045	04/22/05	PFIZER INC	LINEZOLID IN THE TREATMENTOF SUBJECTS WITH COMPLICATEDSKIN AND SOFT TISSUE INFECTION
512	ORTHOPEDICS	PATZAKIS, MICHAEL J MD	400725	11/14/05	THERAVANCE, INC	PHASE III TRIAL OF INTRAVENOUS TELAVANCIN VERSUS VANCOMYCIN
513	ORTHOPEDICS	PATZAKIS, MICHAEL J MD	400730		ARPIDA AG	PHASE III OF A NEW INTRAVENOUSANTIBIOTIC VS INTRAVENOUSLINEZOLID IN COMPLICATED SKIN
514	ORTHOPEDICS	SCHNALL, STEPHEN B MD	681500	09/09/97	DONATIONS	UPPER EXTREMITIES / DR. SCHALLDONATIONS ACCOUNT
515	ORTHOPEDICS	VANGSNESS, THOMAS MD	400935		OMEROS CORPORATION	PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OFOMS103HP
516	ORTHOPEDICS	VANGSNESS, THOMAS MD	401455	10/20/05	REGENERATION TECHNOLOGIES	EVALUATION OF BIOCLEANSE PATELLAR TENDON ALLOGRAFTS FOR CRUCIATE LIGAMENTS
517	ORTHOPEDICS	VANGSNESS, THOMAS MD	400950	07/06/05	OSIRIS THERAPEUTICS	PHASE I/II STUDY OF CHONDROGENADULT UNIVERSAL CELL DELIVEREDBY INTRA-ARTICULAR INJECTION
518	ORTHOPEDICS	VINCE, KELLY MD	444300	05/30/01	ZIMMER, INC	MBK MOBILE BEARING KNEE
519	ORTHOPEDICS	ZALAVRAS, CHARALAMP N	400685	07/11/05	SMITH & NEPHEW	SMITH & NEPHEW GRANT
	<b>ORTHOPEDICS Count</b>	11				
520	OTOLARYNGOLOGY	RICE, DALE MD	401190	08/16/05	IRX THERAPEUTICS	A PHASE 2, OPEN-LABEL TRIAEFFECT OF PRE-OPERATIVE PERI-LYMPHATIC ULTRALOW DOSE I
	<b>OTOLARYNGOLOGY Count</b>	1				
521	PATHOLOGY	AMEZCUA, CHARLIE A MD	226700	06/15/03	HEALTH RESEARCH ASSOCIATION	SUBCELLULAR CHANGES INPROGESTIN TREATED ENDO-METRIAL HYPERPLASIA
522	PATHOLOGY	APPLEMAN, MARIA D	401200	03/03/05	CUBIST PHARMACEUTICALS	SUSCEPTIBILITY TESTING OFCLINICAL ISOLATES OF BACILLUSSPECIES
523	PATHOLOGY	APPLEMAN, MARIA D	552900	07/01/91	MICROBIOLOGY LAB ACCOUNT	LAB / VARIOUS ACCOUNT
524	PATHOLOGY	APPLEMAN, MARIA D	401740	01/18/06	MICROBIOLOGY LAB ACCOUNT	
525	PATHOLOGY	APPLEMAN, MARIA D	400605	05/13/05	CEPHEID	COLLABORATION TARGET ASSAYPLAN
526	PATHOLOGY	TAYLOR, CLIVE R	919200	04/02/80	HLA DIABETES TESTING	HLA DIABETES TESTING

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
	<b>PATHOLOGY Count</b>	6				
527	PEDIATRICS	ELLIOTT, DONNA MD	660300	12/22/95	THE EMMES CORPORATION	CHRONIC RENAL INSUFICIENCY(CRI) ARM OF THE NORTH...
528	PEDIATRICS	ELLIOTT, DONNA MD	496700	12/09/04	GENENTECH INC	GENENTECH NATIONAL COOPERATIVEGROWTH STUDY (NCGS)
529	PEDIATRICS	ESSIN, DANIEL MD	551400	07/01/91	LUNG ASSOCIATION OF	RELATIONSHIP BETWEENVENTILATION & PULMONARY ...
530	PEDIATRICS	HOMANS, JAMES MD	839200	08/01/03	UNIV OF ALABAMA, BIRMINGHAM	CASG 109 SUBCONTRACT
531	PEDIATRICS	KOVACS, ANDREA	456200	05/16/02	TRIANGLE PHARMACEUTICALS IN	EMTRICITABINE IN COMBINATIONANTIRETROVIRAL AGENTS IN HIVINFECTED PEDIATRIC PATIENTS
532	PEDIATRICS	KOVACS, ANDREA	448600	03/27/02	SCHERING PLOUGH RESEARCH	LONG TERM FOLLOW ASSESS PED-IATRIC SUBJECTS AFTER 24 WEEKFOLLOW UP IN SPRI
533	PEDIATRICS	KOVACS, ANDREA	400085		BOEHRINGER INGELHEIM	OPEN LABEL NON-RANDOMIZEDTREATMENT PROTOCOL OF TIPRANA VIR
534	PEDIATRICS	KOVACS, ANDREA	614210	11/06/89	REBILLABLE SALARY ACCOUNT	
535	PEDIATRICS	KOVACS, ANDREA	610710	04/01/03	DONATIONS	MATERNAL & CHILD AIDS PROJECTSUB EDUCATIONAL ACCOUNT
536	PEDIATRICS	NEELY, MICHAEL MD	409700	01/12/05	MERCK & CO.,INC	STUDY TO INVESTIGATE OF 2SEPARATE DOSES OF CASPOFUNGINACETATE IN CHILDREN
537	PEDIATRICS	NEELY, MICHAEL MD	400678	01/30/06	GLAXOSMITHKLINE	STUDY TO COMPARE GW873140 INCOMBINATION (OBT) WITH DRUGRESISTANT CCR5/CXCR4-TROPIC
538	PEDIATRICS	NEELY, MICHAEL MD	400677	01/30/06	GLAXOSMITHKLINE	STUDY TO COMPARE THE EFFICACYAND SAFETY OF GW873140 INCOMBINATION WITH (OBT)
539	PEDIATRICS	NEELY, MICHAEL MD	400676	01/30/06	GLAXOSMITHKLINE	PROSPECTIVE OBSERVATIONALSTUDY OF SUBJECTS WITHCXCR4-TROPIC
540	PEDIATRICS	NEELY, MICHAEL MD	401295		ARK DIAGNOSTICS, INC.	NEW EQUIPMENT ASSAY TESTINGASSOCIATED WITH DRUG LEVELMONITORING OF HIV PATIENTS.
541	PEDIATRICS	NEELY, MICHAEL MD	400675	01/30/06	GLAXOSMITHKLINE	A SCREENING PROTOCOL TO DETER-MINE ELIGIBILITY FOR 1 OF 3PHASE III TREATMENT OF GW87314
542	PEDIATRICS	NEELY, MICHAEL MD	400405		SOLUTION HEALTH SYSTEMS	
543	PEDIATRICS	OPAS, LAWRENCE M	440500	02/01/01	E.H.A. FOUNDATION, INC	EDUCATIONAL: REACH OUT ANDREAD PROGRAM
544	PEDIATRICS	OPAS, LAWRENCE M	400510	03/31/05	HRA / USC	SOM PEDS
545	PEDIATRICS	PORTNOY, BERNARD MD	610700	03/14/89	DONATIONS	MATERNAL & CHILD AIDS PROJECT
546	PEDIATRICS	RAMANATHAN, RANGASAM	401655	12/20/05	DEY, LP	TRIAL COMPARING (SIMV) VS.(NIPPV) AFTER SURFACTANTTREATMENT IN PRETERM INFANTS
547	PEDIATRICS	SPENCER, LASHONDA Y M	480200	02/14/05	GLAXOSMITHKLINE	48 WEEK, PHASE II STUDYPHARMACOKINETICS AND ANTIVIRALACTIVITY OF GW433908
548	PEDIATRICS	STOTTS, CYNTHIA L MD	401670	01/03/06	CHILTERN INTERNATIONAL, INC.	TRIAL COMPARING IMMUNE RESPONSTO PNEUMOCOCCAL CONJUGATEVACCINE GROUP IN INFANTS
549	PEDIATRICS	WEIGENSBERG, MARC J M	672000	01/29/97	GENENTECH INC	GENENTECH NATIONAL COOPERATIVEGROWTH STUDY
550	PEDIATRICS	WU, PAUL Y.K MD	536600	07/01/91	ROSS LABORATORIES	MILK COMPOSITION ON GROWTHFLUID ELECTROLYTE IN ...
551	PEDIATRICS	YANO, SHOJI MD	401880	02/09/06	GENZYME CORPORATION	LYSOSOMAL STORAGE DISORDERSTUDY
	<b>PEDIATRICS Count</b>	25				
552	PHARMACY	RUDIS, MARIA PHD	227300		HRA SEED GRANTS	SALARY SUPPORT
	<b>PHARMACY Count</b>	1				
553	PHYSIOLOGY & BIOSTAT	BERGMAN, RICHARD N MD	455700	01/30/02	BRISTOL-MYERS SQUIBB	EXPLORE THE MECHANISMS OFACTION AND GLUCOVANCE(GLYBURIDE/METFOMIN HC .....
554	PHYSIOLOGY & BIOSTAT	BERGMAN, RICHARD N MD	466200	12/04/02	JANSSEN PHARMACEUTICALS AK	SIX MONTH TRIAL TO EVALUATEGLUCOREGULATORY EFFECTS OFRISPERIDONE AND OLANZAPINE
555	PHYSIOLOGY & BIOSTAT	BERGMAN, RICHARD N MD	401430	10/18/05	AVENTIS PHARMACEUTICALS	EFFECTS OF RIMONABANT ON THECANINE MODEL OF FAT-FEDOBESITY
556	PHYSIOLOGY & BIOSTAT	BERGMAN, RICHARD N MD	401340	09/28/05	ELI LILLY & CO.	ENHANCEMENT OF GLUCOSETOLERANCE BY EXENATIDE ANDGLP-1
557	PHYSIOLOGY & BIOSTAT	BERGMAN, RICHARD N MD	472400	04/08/03	JANSSEN PHARMACEUTICA	EDUCATIONAL ACCOUNT
	<b>PHYSIOLOGY &amp; BIOSTAT</b>	5				

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
558	PSYCHIATRY	DWIGHT, MEGAN MD	426600	02/29/00	PFIZER INC	PATIENTS & CLINICS TOGETHER FOR HEALTH (PACT FOR HEALTH)
559	PSYCHIATRY	LAMB, DORIS	922067	07/01/04	COUNTY OF LOS ANGELES	USC SATELLITE HOUSING
560	PSYCHIATRY	LAMB, DORIS	922058	07/01/05	COUNTY OF LOS ANGELES	USC SATELLITE HOUSING
561	PSYCHIATRY	LAMB, DORIS	922068	07/01/05	COUNTY OF LOS ANGELES	USC SATELLITE HOUSING PROGRAM
562	PSYCHIATRY	MUNJACK, DENNIS J MD	585800	12/09/86	ANXIETY DISORDERS CLINIC	ANXIETY DISORDERS CLINIC OF LAC-USC MEDICAL CENTER ACCOUNT
563	PSYCHIATRY	SCHNEIDER, LON S MD	472600	04/18/03	mitsubishi pharma corporat	SAFETY & EFFICACY OF MKC-231 TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE
564	PSYCHIATRY	SCHNEIDER, LON S MD	497400	10/19/04	SANOI PHARMACEUTICALS INC	18 MONTH STUDY OF EFFICACY OF XALIPRODEN IN PATIENTS W/ MILD TO MODERATE DEMETIA
565	PSYCHIATRY	SCHNEIDER, LON S MD	486900	06/21/04	JOHNSON & JOHNSON CONSUME	OPEN-LABEL EXTENSION STUDY LONG-TERM SAFETY & TOLERABILITY OF GALANTAMINE HBR
566	PSYCHIATRY	SCHNEIDER, LON S MD	488800		PRECISION MED	GENE COLLECTION IN PATIENTS W/ T DEMENTIA OF THE ALZHEIMER'S TYPE
567	PSYCHIATRY	SCHNEIDER, LON S MD	405700	05/31/05	MYRIAD PHARMACEUTICALS	PHASE 3 STUDY OF THE EFFECT DAILY TREATMENT WITH MPC-7869 ON MEASURES OF COGNITIVE
568	PSYCHIATRY	SCHNEIDER, LON S MD	401595	11/29/05	TAKEDA	8 WEEK TREATMENT OF ROZEREM 8MG (QHS) IN SLEEP DISTURBED IN ALZHEIMER'S DISEASE SUBJECT
569	PSYCHIATRY	SIMPSON, GEORGE M	473500	05/23/03	PFIZER INC	12 WEEK, EVALUATION OF DONEPEZIL HYDROCHLORIDE AS ADJUNCTIVE THERAPY
570	PSYCHIATRY	SIMPSON, GEORGE M	400800		ACADIA PHARMACEUTICALS	STUDY TO ASSESS ANTIPSYCHOTIC COGNITIVE & MOTOR EFFECTS OF ACP-103
571	PSYCHIATRY	SIMPSON, GEORGE M	403600	01/03/06	ACADIA PHARMACEUTICALS	STUDY TO DEMONSTRATE EFFICACY OF ACP-103 IN REDUCING NEUROLEPTIC-INDUCED AKATHISIAS
572	PSYCHIATRY	SIMPSON, GEORGE M	490800	05/19/04	ASTRA ZENECA PHARMACEUTICA	MULTICENTER, OPEN-LABEL, FLEXIBLE-DOSE, PARALLEL GROUP EVALUATION OF CATARACTOGENIC
573	PSYCHIATRY	SIMPSON, GEORGE M	402700	01/19/05	GLAXOSMITHKLINE	STUDY TO EVALUATE THE EFFICACY & SAFETY OF A FLEXIBLE DOSE OF LAMOTRIGINE
574	PSYCHIATRY	SIMPSON, GEORGE M	401440	10/18/05	ASTRA ZENECA PHARMACEUTICA	FRONT LOADING OF QUETIAPINE IN MANAGEMENT OF AGITATION IN AN INNER CITY PSYCHIATRIC DEPT
575	PSYCHIATRY	SIMPSON, GEORGE M	401395	10/13/05	EISAI AMERICA, INC.	A PILOT STUDY OF THE EFFECTS OF DONEPEZIL AUGMENTATION OF LITHIUM THERAPY
576	PSYCHIATRY	SIMPSON, GEORGE M	401695	01/06/06	JANSSEN, L.P.	2-YEAR STUDY OF EFFICACY & EFFECTIVENESS OF RISPERDAL CONSTA & ARIPEPRAZOLE
	<b>PSYCHIATRY Count</b>	19				
577	RADIATION ONCOLOGY	KUMAR, PARVESH MD	487900	04/06/04	RADIATION ONCOLOGY TITHING	RADIATION ONCOLOGY TITHING ACCOUNT
578	RADIATION ONCOLOGY	KUMAR, PARVESH MD	487400	03/26/04	PHARMACYCLICS, INC	PHASE III TRIAL OF XCYTRIN (MOTEXAFIN GADOLINIUM) INJECTION TREATMENT BRIAN
579	RADIATION ONCOLOGY	KUMAR, PARVESH MD	409100		UNIVERSITY OF CHICAGO	PHASE III TRIAL OF DOCETAXEL BASED INDUCTION CHEMOTHERAPY IN PATIENTS WITH N2/N3
580	RADIATION ONCOLOGY	KUMAR, PARVESH MD	409500		AMGEN INC.	PHASE III STUDY OF PALIFERMININ REDUCING MUCOSITIS IN PATIENTS W/ T ADVANCED HEAD
581	RADIATION ONCOLOGY	STREETER, OSCAR MD	479700	10/20/03	PROXIMA THERAPEUTICS, INC.	PHASE II NON-RANDOMIZED STUDY OF MAMMOSITE RTS AS SOLERADIATION THERAPY TECHNIQUE
	<b>RADIATION ONCOLOGY C</b>	5				
582	RADIOLOGY	DUDDALWAR, VINAY MD	401825	02/07/06	BRACCO DIAGNOSTICS INC.	PREDICT STUDY
583	RADIOLOGY	GO, JOHN MD	467500	12/23/02	BRACCO DIAGNOSTICS INC.	MULTIHANCE IN CONTRAST-ENHANCED MAGNETIC RESONANCE ANGIOGRAPHY (MRA) IN ASSESSMENT OF CAROTID
584	RADIOLOGY	GRANT, EDWARD MD	437900	12/28/00	RADIOLOGY TITHING ACCOUNT	RADIOLOGY TITHING ACCOUNT
585	RADIOLOGY	GRANT, EDWARD MD	478900	09/16/03	AMERSHAM HEALTH	EVALUATION OF USE ULTRASOUND CONTRAST AGENT, OPTISON, IN LIVER, PANCREAS OR RENAL

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
586	RADIOLOGY	KATZ, MICHAEL MD	463800	09/23/02	BRACCO DIAGNOSTICS INC.	MULTIHANCE, ENHANCED (CE) MAG-NETIC RESONANCE ANGIOGRAPHY(MRA) IN ASSESSMENT OF RENAL
587	RADIOLOGY	PARISKY, YURI R MD	406200	03/15/05	HOLOGIC INC	SINGLE CENTER FEASIBILITY EVALUATION OF CONTRAST AGENT MAMMOGRAPHY IMAGING
588	RADIOLOGY	PARISKY, YURI R MD	401610	11/30/05	HOLOGIC INC	FEASIBILITY EVALUATION OF REDUCED-DOSE DIGITAL MAMMO-GRAPHY USING TUNGSTEN X-RAY
589	RADIOLOGY	SEGALL, HERVEY D MD	528300	07/01/91	UNIV CHILDRENS MEDICAL GROUP	NEUROLOGICAL EYE & RADIOLOGY RESEARCH FUND
590	RADIOLOGY	SHETH, PULIN A MD	400075	06/03/05	DOBI MEDICAL INTERNATIONAL	BLINDED-READER STUDY TO DETERMINE THE SENSITIVITY & SPECIFICITY OF THE COMFORTSCAN
	<b>RADIOLOGY Count</b>	9				
591	SURGERY	BEART, ROBERT W MD	483700	01/20/04	COLORECTAL SURGERY TITHING	DEPARTMENT OF COLORECTAL SURGERY TITHING ACCOUNT
592	SURGERY	BEART, ROBERT W MD	401135	08/02/05	MACROPORE BIOSURGERY, INC	EVALUATION OF SURGIWRAP TO MINIMIZE SOFT TISSUE ATTACHMENT & REDUCE THE INCIDENCE
593	SURGERY	BEART, ROBERT W MD	498200		GLAXOSMITHKLINE	PROSPECTIVE EVALUATION OF THE BURDEN OF POSTOPERATIVE ILEUS & OPIOID BOWEL DYSFUNCTION
594	SURGERY	BELZBERG, HOWARD MD	474900	07/11/03	AMPHASTAR PHARMACEUTICALS	COMPARATIVE SAFETY & EFFICACY OF AMPOFOL & DIPRIVAN FOR SEDATION OF INTENSIVE CARE
595	SURGERY	BELZBERG, HOWARD MD	400870		AMGEN INC.	STUDY TO EVALUATE THE ERYTHROPOIETIC RESPONSIVENESS ASSOCIATED WITH ONCE-WEEKLY (Q
596	SURGERY	BELZBERG, HOWARD MD	403100	12/14/04	GLAXOSMITHKLINE	STUDY OF THREE DAYS CONTINUOUS INTRAVENOUS INFUSION OF GR270773
597	SURGERY	BELZBERG, HOWARD MD	491900	06/28/04	ALTANA PHARMA	VENTICUTE (RSP-C SURFACTANT) IN PATIENTS W/T PNEUMONIA
598	SURGERY	BREMNER, CEDRIC G MD	401555	11/15/05	RESPIRATORY TECHNOLOGY CO	MEASUREMENT OF REFLUX IN THE PHARYNX: A NEW TECHNOLOGY RESPIRATORY CORPORATION
599	SURGERY	DEMETRIADES, DEMETRIO	400990		PRONEURON BIOTECHNOLOGIES	PHASE II STUDY OF AUTOLOGOUS MACROPHAGES FOR THE TREATMENT OF COMPLETE SPINAL CORD INJURIES
600	SURGERY	DEMETRIADES, DEMETRIO	228100	10/01/05	HRA SEED GRANTS	TRAUMA RESEARCH FELLOWS FUND
601	SURGERY	GENYK, YURI MD	401265	12/20/05	ZYMOGENETICS	PHASE 3, STUDY OF (RH THROMBIN AND (BOVINE THROMBIN) IN SURGICAL HEMOSTASIS
602	SURGERY	HOLMES, DENNIS MD	404200	08/31/05	TARGIT INTERNATIONAL STEERING	AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO COMPARE TARGETED INTRA- OPERATIVE
603	SURGERY	JABBOUR, NICHOLAS MD	400035	08/15/05	GENZYME CORPORATION	STUDY OF THYMOGLOBULIN INDUCTION THERAPY WITH A CALCINEURIN-INHIBITOR
604	SURGERY	KAUFMAN, HOWARD MD	481700	02/02/04	MEDTRONIC	INTERSTIM SACRAL NERVE STIMULATION FOR BOWEL CONTROL FECAL INCONTINENCE STUDY
605	SURGERY	KAUFMAN, HOWARD MD	494800	07/16/04	CURON MEDICAL INC.	TRIAL INVESTIGATING SUBMUCOSAL DELIVERY OF RADIOFREQUENCY ENERGY TO ANAL CANAL
606	SURGERY	KAUFMAN, HOWARD MD	400590	09/06/05	SYNOVIS SURGICAL INNOVATION	PERI-STRIPS DRY WITH VERITAS COLLAGEN MATRIX STAPLE LINE PROTECTION FOR COLORECTAL
607	SURGERY	MATEO, ROD MD	469200	03/03/03	FUJISAWA HEALTHCARE, INC	PATIENT OUTCOMES REGISTRY FOR TRANSPLANT EFFECTS ON LIFE
608	SURGERY	MATEO, ROD MD	401540	11/08/05	ISOTECHNIKA INC.	PHASE IIB STUDY OF ISA247 AND TACROLIMUS (PROGRAF) IN DE NOVO RENAL TRANSPLANT PATIENTS
609	SURGERY	MATEO, ROD MD	400120	03/31/05	NOVARTIS PHARMACEUTICALS CO	A THREE MONTH TWO COHORT STUDY TO INVESTIGATE THE SAFETY & TOLERABILITY OF MYFORTIC®
610	SURGERY	MATEO, ROD MD	400680	09/06/05	NOVARTIS PHARMACEUTICALS CO	COMPARATIVE STUDY OF TOLERABILITY & OUTCOME OF MYFORTIC®/CELLCEPT® IN KIDNEY TRANSPLANT
611	SURGERY	MATEO, ROD MD	477900	09/03/03	FUJISAWA HEALTHCARE, INC	PHASE III STUDY TO ASSESS THE SAFETY & EFFICACY OF PROGRAF/MMF, MODIFIED RELEASE (MR)

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
612	SURGERY	MATEO, ROD MD	492300	08/16/04	SANGSTAT MEDICAL CORPORATI	PHASE II STUDY COMPARINGTHYMOGLOBULIN IN RAPID DIS-CONTINUATION OF CORTICOSTEROID
613	SURGERY	NUNOO-MENSAH, JOSEPH	404900	01/31/05	BAYER CORPORATION	MATERIAL SUPPLY AGREEMENTNO FUNDING
614	SURGERY	REISS, MATTHEW MD	407500		PFIZER INC	MATERIAL AGREEMENT:PFIZER COMPOUND SC-58635(CELECOXIB / CELEBREX)
615	SURGERY	RHEE, PETER MD	401100	11/22/04	HUTCHINSON TECHNOLOGY	AN EVALUATION OF THE INSPECTRATISSUE SPECTROMETER DURINGTRAUMATIC SHOCK RESUSCITATION
616	SURGERY	RHEE, PETER MD	400566		HENRY M. JACKSON FOUNDATION	A PIVOTAL, RANDOMIZED CON-TROLLED & SINGLE-BLINDED TRIALOF THE HEMOGLOBIN BASED OXYGEN
617	SURGERY	RHEE, PETER MD	839100	06/01/05	HENRY M. JACKSON FOUNDATION	WIRELESS VITAL SIGNS MONITOR
618	SURGERY	RHEE, PETER MD	839500	07/01/05	HENRY M. JACKSON FOUNDATION	RESUS CONSORTIUM SUBWARD
619	SURGERY	RHEE, PETER MD	400565		HENRY M. JACKSON FOUNDATION	RESUS SUBAWARD CONSORTIUMSTUDY CLOSED AND OPEN 839500
620	SURGERY	RHEE, PETER MD	407600	11/09/05	NOVO NORDISK	TRIAL TO EVALUATEACTIVATED RECOMBINANT FACT VII IN INJURED TRAUMA SUBJECTS
621	SURGERY	ROWE, VINCENT L MD	401325		SANOFI-AVENTIS	VASCULAR STUDY
622	SURGERY	SALIM, ALI MD	400505		TAKEDA	SAFETY AND EFFICACY OF TAK-242IN ADULTS WITH SEVERESEPSIS
623	SURGERY	SHER, LINDA MD	463200	08/22/02	BAYLOR COLLEGE OF MEDICINE	3 IMMUNOSUPPRESSANT TRTMNTREGIMENS IN PATIENTS RECEIVINGA LIVER TRANSPLANT FOR END
624	SURGERY	SHER, LINDA MD	400815		ROCHE LABORATORIES, INC	TRIAL OF THE EFFICACY & SAFETYLONG TERM CALCINEURIN INHIBA-TOR FREE MAINTENANCE REGIMEN
625	SURGERY	SHER, LINDA MD	464700	10/10/02	THERMOGENESIS CORPORATION	TRIAL USING FIBRIN SEALANT,PRODUCED BY THE CRYOSEAL FSSYSTEM, IN PATIENTS UNDERGOING
626	SURGERY	SHER, LINDA MD	486100	02/09/04	CELLZDIRECT	HEPATIC RESEARCH REGISTRYCOLLECTION OF NORMAL LIVERTISSUE
627	SURGERY	SILBERMAN, HOWARD MD	563000	07/01/91	ABBOTT LABORATORIES	EFFECT INTENSIVE PAREXTERAL-ENTERAL FEEDING EUTHYROID...
628	SURGERY	SILVERSTEIN, MELVIN MD	440200	02/15/01	ETHICON ENDO-SURGERY	DRAINAGE VOLUME IN SIMPLE &MODIFIED RADICAL ...
629	SURGERY	TOWFIGH, SHIRIN MD	400330	12/05/05	GENZYME CORPORATION	PHASE III STUDY OF GT267-004VERSUS VANCOMYCIN, AND GT267-004
630	SURGERY	TOWFIGH, SHIRIN MD	401070	07/18/05	SIRG TITHING ACCOUNT	SIRG TITHING ACCOUNT(SURGICAL INFECTION RESEARCHGROUP)
631	SURGERY	TOWFIGH, SHIRIN MD	400835	01/17/06	CADENCE PHARMACEUTICALS	PHASE III STUDY TO ASSESS THEEFFICACY OF TOPICAL ADMINI-STRATION OF OMIGANAN 1.0% GEL
632	SURGERY	TOWFIGH, SHIRIN MD	400705	12/14/05	WYETH-AYERST PHARMACEUTIC	COMPARATIVE STUDY OF TIGECYCLIVS. CEFTRIAZONE SODIUM PLUSMETRONIDAZOLE
633	SURGERY	TOWFIGH, SHIRIN MD	409900	05/04/05	THERAVANCE, INC	PHASE III TRIAL OF INTRAVENOUS TELAVANCIN VERSUS VANCOMYCINFOR TREATMENT OF COMPLICATED
634	SURGERY	TOWFIGH, SHIRIN MD	400850	08/10/05	KIMBERLY CLARK HEALTH CARE	CLINICAL TRIAL OF MEDLOGIC SURGICAL SKIN SEALANT AND THE PREVENTION OF SURGICAL WOUND
635	SURGERY	TOWFIGH, SHIRIN MD	401520	11/04/05	PENINSULA PHARMACEUTICALS	STUDY OF DORIPENEM VERSUSPIPERACILLIN-TAZOBACTAM IN THETREATMENTOF SKIN INFECTIONS
636	SURGERY	TOWFIGH, SHIRIN MD	400030	06/16/05	THERAVANCE, INC	PHASE 3 OF INTRAVENOUS TELAVANVS. VANCOMYCIN FOR TREATMENTHOSPITAL-ACQUIRED PNEUMONIA
637	SURGERY	WEAVER, FRED A MD	667200	06/28/96	REBILLABLE SALARY ACCOUNT	
638	SURGERY	WEAVER, FRED A MD	486200	02/09/04	VASOGEN, INC	STUDY OF IMMUNE MODULATIONTHERAPY IN IMPROVING WALKINGDISTANCE IN PATIENTS
639	SURGERY	WEAVER, FRED A MD	487300	02/23/04	NUVELO	PHASE II OPEN-LABEL DOSE-ES-CALATION STUDY OF ALFIMEPRASEW/T ACUTE PERIPHERAL ARTERIAL
640	SURGERY	WEAVER, FRED A MD	400550	05/17/05	NUVELO	PHASE 3 STUDY OF ALFIMEPRASEIN SUBJECTS W/T ACUTE PERIPHERARTERIAL OCCLUSION (NAPA-2)
641	SURGERY	WEAVER, FRED A MD	401260	09/01/05	ZYMOGENETICS	PHASE 3, STUDY OF TOPICALRECOMBINANT HUMAN THROMBIN ANDTHROMBIN-JIMI IN SURGICAL HEMO
	<b>SURGERY Count</b>	51				

**HEALTH RESEARCH ASSOCIATION**  
List of Industry-Sponsored Funded Investigators

	DEPARTMENT	PI NAME	HRA PROJECT	START DATE	SPONSOR	TITLE
642	UROLOGY	GINSBERG, DAVID MD	400615	09/09/05	ALLERGAN INC	DOSE-RESPONSE STUDY OF SAFETY & EFFICACY OF A SINGLE TREATMENT OF BOTOX®
643	UROLOGY	GINSBERG, DAVID MD	401075		ALLERGAN INC	
644	UROLOGY	GINSBERG, DAVID MD	401435	10/18/05	PFIZER INC	
645	UROLOGY	PENSON, DAVID F MD	401000	11/21/04	AMGEN INC.	STUDY TO EVALUATE AMG 162 BONE LOSS IN SUBJECTS UNDER-GOING ANDROGEN DEPRIVATION
646	UROLOGY	PENSON, DAVID F MD	400780	10/07/05	DENDREON CORPORATION	PHASE 3 TRIAL OF IMMUNOTHERAPY WITH AUTOLOGOUS ANTIGEN PRESENTING CELLS LOADED PA2024
647	UROLOGY	PENSON, DAVID F MD	400782	10/07/05	DENDREON CORPORATION	AN OPEN LABEL SINGLE ARM TRIAL OF IMMUNOTHERAPY WITH AUTO-LOGOUS ANTIGEN PRESENTING CELL
648	UROLOGY	PENSON, DAVID F MD	401235		PHOTOCURE ASA	STUDY OF HEXVIX FLOURESCENCE IN DETECTION OF PAPILLARY BLADDER CANCER
649	UROLOGY	PENSON, DAVID F MD	401640	12/15/05	ENVISIONEERING MEDICAL TECHNOL	
650	UROLOGY	PENSON, DAVID F MD	400781		DENDREON CORPORATION	IMMUNE MONITORING SUB-PROTOCOL TO TRIAL D9902B
651	UROLOGY	SKINNER, EILA	461200	08/30/02	SCHERING CORPORATION	TRIAL OF INDUCTION & 6 COURSES OF 3 WEEK MAINTENANCE WITH BCGVS. BCG
	<b>UROLOGY Count</b>	10				
	<b>Grand Count</b>	651				